Clinical Professor Murray Barclay

2025

Journal - Research Article

Sundermann, M., Every-Palmer, S., Barclay, M., & Chin, P. K. L. (2025). A clinical decision support alert to promote timely laxative use in in-patients prescribed clozapine. BJPsych Open, 11, e51. doi: 10.1192/bjo.2025.1

2024

Journal - Research Article

Kaur, G., Barclay, M., Mitchell, J., Jordan, S., & Stebbings, S. (2024). The prevalence and clinical features of leflunomide-associated peripheral neuropathy in patients with rheumatic disease in a New Zealand cohort. International Journal of Rheumatic Diseases, 27, e15317. doi: 10.1111/1756-185x.15317

Keating, P. E., Hock, B. D., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2024). Evaluation of the homogenous mobility shift assay for infliximab and adalimumab anti-drug antibody detection in the clinical laboratory. Therapeutic Drug Monitoring. Advance online publication. doi: 10.1097/ftd.0000000000001200

Stamp, L. K., Keating, P., Frampton, C., Barclay, M. L., Fanning, N., Millier, M., Hessian, P. A., & O'Donnell, J. L. (2024). Relationship between adalimumab concentrations, anti-drug antibodies and disease activity in rheumatoid arthritis: A cross-sectional observational study. Journal of Rheumatology, 51(3), 242-249. doi: 10.3899/jrheum.2023-0706

Stamp, L. K., Horsley, C., Te Karu, L., Dalbeth, N., & Barclay, M. (2024). Colchicine: The good, the bad, the ugly, and how to minimise the risks. Rheumatology, 63, 936-944. doi: 10.1093/rheumatology/kead625

Journal - Research Other

Alsoud, D., Moes, D. J. A. R., Wang, Z., Soenen, R., Layegh, Z., Barclay, M., … Dreesen, E. (2024). Best practice for therapeutic drug monitoring of infliximab: Position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring. Advance online publication. doi: 10.1097/ftd.0000000000001204

Conference Contribution - Published proceedings: Abstract

Alfeld, K., Barclay, M., Dalrymple-Alford, J., McNeill, R., Frampton, C., Doogue, M., & Stamp, L. (2024). In-patient management of gout: We are still failing. International Journal of Rheumatic Diseases, 27(Suppl. 2), O01. doi: 10.1111/1756-185X.15171

2023

Journal - Research Article

Butler, J. M., Frampton, C. M., Moore, G., Barclay, M. L., & Jardine, D. L. (2023). Immediate effect of caffeine on sympathetic nerve activity: Why coffee is safe? A single-centre crossover study. Clinical Autonomic Research, 33, 623-633. doi: 10.1007/s10286-023-00967-5

Wang, M., Barclay, M. L., Chin, P. K. L., & Doogue, M. P. (2023). Changes in inpatient medicine prescribing during Covid-19 lockdown. Internal Medicine Journal, 53, 917-922. doi: 10.1111/imj.15996

Journal - Research Other

Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing [Brief communication]. Internal Medicine Journal, 53(11), 2123-2127. doi: 10.1111/imj.16264

Crouwel, F., Simsek, M., van Doorn, A. S., Mulder, C. J. J., Buiter, H. J. C., Barclay, M. L., … de Boer, N. K. (2023). Rectally administrated thioguanine for distal ulcerative colitis: A multicenter case series [Brief report]. Inflammatory Bowel Diseases, 29, 1000-1004. doi: 10.1093/ibd/izac195

Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Keating, P. E., Hock, B. D., Chin, P. K. L., & O'Donnell, J. L. (2023). Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 235. Retrieved from https://www.asceptasm.com

Barclay, M. L., Ovenden, C., Anderson, A., & Chou, E. (2023). Thioguanine efficacy, safety and TDM in IBD patients in New Zealand. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P514. Retrieved from https://www.asceptasm.com

Barclay, M. L., Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., & O'Donnell, J. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating high potential for improved dosing. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P513. Retrieved from https://www.asceptasm.com

2022

Journal - Research Article

Kubovy, J., & Barclay, M. L. (2022). Helicobacter pylori in New Zealand: Current diagnostic trends and related costs. New Zealand Medical Journal, 135(1562), 48-55. Retrieved from https://journal.nzma.org.nz/

Liu, Z., Julsgaard, M., Zhu, X., Martin, J., Barclay, M., Cranswick, N., … Gearry, R., … the CARINA Study Group. (2022). Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children. Journal of Crohn's & Colitis, 16, 1835-1844. doi: 10.1093/ecco-jcc/jjac093

Journal - Research Other

Kee, P. S., Maggo, S. D. S., Kennedy, M. A., Barclay, M. L., Miller, A. L., Lehnert, K., … Chin, P. K. L. (2022). Omeprazole treatment failure in gastroesophageal reflux disease and genetic variation at the CYP2C locus [Brief research report]. Frontiers in Genetics, 13, 869160. doi: 10.3389/fgene.2022.869160

Conference Contribution - Verbal presentation and other Conference outputs

Kee, P. S., Maggo, S., Kennedy, M. A., Barclay, M. L., Miller, A., Lehnert, K., … Faull, R. L. M., … Chin, P. K. L. (2022, August-September). Omeprazole treatment failure in gastro-oesophageal reflux disease and genetic variation at the CYP2C locus. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.

2021

Journal - Research Article

Thomas, P. W. A., Chin, P. K. L., & Barclay, M. L. (2021). A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Internal Medicine Journal, 51(3), 341-347. doi: 10.1111/imj.14778

2020

Journal - Research Article

van Doorn, A. S., Meijer, B., Frampton, C. M. A., Barclay, M. L., & de Boer, N. K. H. (2020). Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Alimentary Pharmacology & Therapeutics, 52, 1276-1288. doi: 10.1111/apt.16036

Chin, P. K. L., Chuah, Q., Crawford, A. M., Clendon, O. R., Drennan, P. G., Dalrymple, J. M., Barclay, M. L., & Doogue, M. P. (2020). Clinical decision support in a hospital electronic prescribing system informed by local data: Experience at a tertiary New Zealand centre. Internal Medicine Journal, 50, 1225-1232. doi: 10.1111/imj.14706

McCombie, A., Walmsley, R., Barclay, M., Ho, C., Langlotz, T., Regenbrecht, H., Gray, A., … Inns, S., & Schultz, M. (2020). A noninferiority randomized clinical trail of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients. Inflammatory Bowel Diseases, 26(7), 1098-1109. doi: 10.1093/ibd/izz252

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Merriman, T. R., Wright, D. F. B., … Dalbeth, N. (2020). Relationships between allopurinol dose, oxypurinol concentration and urate-lowering response: In search of a minimum effective oxypurinol concentration. Clinical & Translational Science, 13, 110-115. doi: 10.1111/cts.12686

Journal - Research Other

McNeill, R. P., & Barclay, M. L. (2020). Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Current Opinion in Pharmacology, 55, 41-46. doi: 10.1016/j.coph.2020.09.006

Conference Contribution - Published proceedings: Abstract

Mules, T., Stedman, C. A., Ding, S., Burt, M., Gearry, R., Chalmers-Watson, T., Falvey, J., Chapman, B., Barclay, M. L., Lim, G., … Ngu, J. H. (2020). The ABC score accurately predicts mortality in hospitalized patients that develop upper gastrointestinal bleeding. Gastrointestinal Endoscopy, 91(6, Suppl.), (pp. AB590-AB591). doi: 10.1016/j.gie.2020.03.3668

2019

Journal - Research Article

International Multiple Sclerosis Genetic Consortium, including Mason, D., & Barclay, M. (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 365, eaav7188. doi: 10.1126/science.aav7188

Stamp, L. K., O'Donnell, J. L., Frampton, C., Drake, J., Zhang, M., Barclay, M., & Chapman, P. (2019). A pilot randomized controlled double-blind trial of high- versus low-dose weekly folic acid in people with rheumatoid arthritis receiving methotrexate. Journal of Clinical Rheumatology, 25(7), 284-287. doi: 10.1097/RHU.0000000000000848

Romagnoni, A., Jégou, S., Van Steen, K., Wainrib, G., Hugot, J.-P., and International Inflammatory Bowel Disease Genetics Constortium (IIBDGC), including Barclay, M., Gearry, R., & Roberts, R. L. (2019). Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Scientific Reports, 9, 10351. doi: 10.1038/s41598-019-46649-z

Barclay, M. L., Karim, S., Helms, E. T. J., Keating, P. E., Hock, B., Stamp, L. K., & Schultz, M. (2019). Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal, 49, 513-518. doi: 10.1111/imj.14064

Journal - Research Other

Khan, A., Boyke Berahmana, A., Day, A. S., Barclay, M. L., & Schultz, M. (2019). New Zealand Society of Gastroenterology guidelines on therapeutic drug monitoring in inflammatory bowel disease. New Zealand Medical Journal, 132(1491), 46-62. Retrieved from https://www.nzma.org.nz/journal

de Boer, N. K. H., on behalf of the Thiopurine Working Group, including Barclay, M. L., & Gearry, R. B. (2019). Thiopurine therapy in inflammatory bowel diseases: Making new friends should not mean losing old ones. Gastroenterology, 156, 11-19. doi: 10.1053/j.gastro.2018.11.039

Conference Contribution - Published proceedings: Abstract

Stamp, L., Keating, P., Frampton, C., Barclay, M., Fanning, N., Millier, M., Hessian, P., & O'Donnell, J. (2019). Relationship between adalimumab concentrations, plasma cytokines, anti-drug antibodies and disease activity in rheumatoid arthritis. Arthritis & Rheumatology, 71(Suppl. 10), 1440. doi: 10.1002/art.41108

Stamp, L., Chapman, P., Barclay, M., Horne, A., Frampton, C., Merriman, T., Wright, D., … Dalbeth, N. (2019). Relationships between allopurinol dose, oxypurinol levels and serum urate: In search of an oxypurinol therapeutic concentration. Arthritis & Rheumatology, 71(Suppl. 10), 1222. doi: 10.1002/art.41108

Walmsley, R., McCombie, A., Barclay, M., Visesio, N., Ho, C., Brown, S., Rosser, K., … Gray, A., Regenbrecht, H., Langlotz, T., & Schultz, M. (2019). A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc^® in the care of inflammatory bowel disease patients. Journal of Crohn's & Colitis, 13(Suppl. 1), (pp. S432-S433). doi: 10.1093/ecco-jcc/jjy222.754

2018

Journal - Research Article

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research & Therapy, 20, 255. doi: 10.1186/s13075-018-1755-0

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology, 57(12), 2183-2189. doi: 10.1093/rheumatology/key237

Momozawa, Y., Dmitrieva, J., Théātre, E., Deffontaine, V., Rahumouni, S., Charloteaux, B., … The International IBD Genetics Consortium, including Barclay, M., … Georges, M. (2018). IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nature Communications, 9(1), 2427. doi: 10.1038/s41467-018-04365-8

Roberts, R. L., Wallace, M. C., Seinen, M. L., van Bodegraven, A. A., Krishnaprasad, K., Jones, G. T., van Rij, A. M., … Kennedy, M. A., … Gearry, R. B., … Barclay, M. (2018). Nonsynonymous polymorphism in guanine monophosphate synthetase is a risk factor for unfavorable thiopurine metabolite ratios in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 24(12), 2606-2612. doi: 10.1093/ibd/izy163

Chambers, C. N. L., Frampton, C. M. A., McKee, M., & Barclay, M. (2018). 'It feels like being trapped in an abusive relationship': Bullying prevalence and consequences in the New Zealand senior medical workforce: A cross-sectional study. BMJ Open, 8(3), e020158. doi: 10.1136/bmjopen-2017-020158

Munning-Schmidt, E., Zhang, M., Mulder, C. J., & Barclay, M. L. (2018). Late-onset rise of 6-MMP metabolites in IBD patients on azathioprine or mercaptopurine. Inflammatory Bowel Diseases, 24(4), 892-896. doi: 10.1093/ibd/izx081

Wright, D. F. B., Dalbeth, N., Phipps-Green, A. J., Merriman, T. R., Barclay, M. L., Drake, J., … Stamp, L. K. (2018). The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. British Journal of Clinical Pharmacology, 84(5), 937-943. doi: 10.1111/bcp.13516

Journal - Research Other

Barclay, M. L., & Stamp, L. K. (2018). Vedolizumab as a treatment and cause of extra-intestinal manifestations of inflammatory bowel disease [Invited]. Alimentary Pharmacology & Therapeutics, 47(4), 535-536. doi: 10.1111/apt.14465

Stamp, L. K., & Barclay, M. L. (2018). How to prevent allopurinol hypersensitivity reactions? Rheumatology, 57(1), i35-i41. doi: 10.1093/rheumatology/kex422

Conference Contribution - Published proceedings: Abstract

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2018). Internal deterministic identifiability of PK and PKPD models. Proceedings of the 19th Annual Population Approach Group in Australia and New Zealand Meeting (PAGANZ). Retrieved from http://paganz.org

Nichols, G., Dobbs, B., Schultz, M., Barclay, M., & Farella, M. (2018). Simultaneous monitoring of intraoral and oesophageal acidity: Is there an association? European Journal of Orthodontics, 40(5), (pp. e151). doi: 10.1093/ejo/cjy060

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2018). Assessing for the completedness of a QSP model for azathioprine metabolism. Proceedings of the 19th Annual Population Approach Group in Australia and New Zealand Meeting (PAGANZ). Retrieved from http://paganz.org

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomized controlled trial. Arthritis & Rheumatology, 70(9, Suppl.), 2229. doi: 10.1002/art.40700

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2018). Determining the structure of a quantitative systems pharmacology (QSP) model for azathioprine metabolism. Journal of Pharmacokinetics & Pharmacodynamics, 45(Suppl. 1), (pp. S46-S47). doi: 10.1007/s10928-018-9606-9

Stamp, L., Chapman, P., Barclay, M., Horne, A., Tan, P., Drake, J., & Dalbeth, N. (2018). Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomized controlled trial. Scandinavian Journal of Rheumatology, 47(Suppl. 129), (pp. 40-41). doi: 10.1080/03009742.2018.1487639

Conference Contribution - Verbal presentation and other Conference outputs

Thomas, P. W. A., Chin, P. K. L., Doogue, M. P., & Barclay, M. L. (2018, August). A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

Zhang, M., Thomas, P. W. A., & Barclay, M. L. (2018, August). Stability of 6-thioguanine in mesalazine enemas: A possible future proctitis treatment. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2017

Journal - Research Article

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: A post hoc analysis of a randomized controlled trial. Arthritis Research & Therapy, 19(1), 283. doi: 10.1186/s13075-017-1491-x

Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., … IBD Sydney Organisation, and the Australian Inflammatory Bowel Diseases Consensus Working Group. (2017). Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics, 46(11-12), 1037-1053. doi: 10.1111/apt.14368

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6 mg/dL: An open-label extension study. Annals of the Rheumatic Diseases, 76(12), 2065-2070. doi: 10.1136/annrheumdis-2017-211873

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2017). Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models. Journal of Pharmacokinetics & Pharmacodynamics, 44(5), 415-423. doi: 10.1007/s10928-017-9530-4

Kannangara, D. R. W., Graham, G. G., Wright, D. F. B., Stocker, S. L., Portek, I., Pile, K. D., Barclay, M. L., … Stamp, L. K., & Day, R. O. (2017). Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology, 83(9), 2015-2026. doi: 10.1111/bcp.13307

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases, 76(9), 1522-1528. doi: 10.1136/annrheumdis-2016-210872

Chambers, C., Frampton, C., & Barclay, M. (2017). Presenteeism in the New Zealand senior medical workforce: A mixed-methods analysis. New Zealand Medical Journal, 130(1449), 10-21. Retrieved from https://www.nzma.org.nz/journal

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2017). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 73, 71-78. doi: 10.1007/s00228-016-2133-y

Journal - Professional & Other Non-Research Articles

Kamel, K. S., Chin, P. K. L., Doogue, M. P., & Barclay, M. L. (2017). Comment on: "Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study>". Clinical Pharmacokinetics, 56(2), 207-208. doi: 10.1007/s40262-016-0481-5

Conference Contribution - Published proceedings: Abstract

Nichols, G., Farella, M., Dobbs, B., Schultz, M., & Barclay, M. (2017). Cross-correlation analysis of intra-oral and esophageal pH in patients with gastro-esophageal reflux disorder (GORD): A pilot study. Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. 56. Retrieved from http://gastro2017.co.nz

McCombie, A., Walmsley, R., Barclay, M., Visesio, N., Ho, C., Brown, S., … Inns, S., & Schultz, M. (2017). Adherence and usability of the smartphone apps IBDsmart and IBDoc©. Proceedings of the New Zealand Society of Gastroenterology and the NZNO Gastroenterology Nurses' College Annual Scientific Meeting. 42. Retrieved from http://gastro2017.co.nz

Zhang, M., Moore, G. A., Doogue, M. P., & Barclay, M. L. (2017). Simultaneous determination of adalimumab and infliximab in human serum by liquid chromatography/tandem mass spectrometry. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 60). Retrieved from http://www.asceptasm.com/

Doogue, M., McNeill, R., Young, M., Wilkinson, J., Pugh, S., Sylevych, V., … Chuah, Q., Hamilton, N., Chua, I., … Barclay, M., & Chin, P. (2017). Making adverse drug reactions visible. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 49). Retrieved from http://www.asceptasm.com/

Barclay, M. L., Munning-Schmidt, E., Zhang, M., & Mulder, C. J. (2017). Late onset rise of 6-MMP metabolites in inflammatory bowel disease patients on azathioprine or mercaptopurine. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 55). Retrieved from http://www.asceptasm.com/

Wright, D. F. B., Phipps-Green, A., Merriman, T. R., Barclay, M. L., Dalbeth, N., & Stamp, L. K. (2017). The influence of ABCG2 genotype on allopurinol dose predictions. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting. (pp. 55). Retrieved from http://www.asceptasm.com/

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6mg/Dl: An open label extension study. Arthritis & Rheumatology, 69(Suppl. 10), 1105. doi: 10.1002/art.40321

Doogue, M., McGowan, A., Barclay, M., & Jardine, D. (2017). Multimorbidity, guidelines and polypharmacy. Clinical Therapeutics, 39(8, Suppl.), (pp. e17-e18). doi: 10.1016/j.clinthera.2017.05.055

O'Donnell, J., Liu, J., Keating, P., Hock, B., Spellerberg, M., Barclay, M., & Stamp, L. (2017). Anti-drug antibodies (ADA): Assay performance in patients treated for inflammatory bowel and rheumatic disease with biodrugs, adalimumab and infliximab. Internal Medicine Journal, 47(Suppl. 2), (pp. 15). doi: 10.1111/imj.13426

Conference Contribution - Verbal presentation and other Conference outputs

Siripuram, V. K., Duffull, S. B., Wright, D. F. B., & Barclay, M. L. (2017, September). Predicting the clinical response to thiopurine therapy in inflammatory bowel disease: A model based approach. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

Walsh, S., Barclay, M., Lunt, H., & McLaughlin, J. (2017, May). Impact of liver disease and its management on glycated haemoglobin values. Verbal presentation at the New Zealand Society for the Study of Diabetes (NZSSD) Annual Scientific Meeting, Dunedin, New Zealand.

2016

Journal - Research Article

Huelsen, A., Fischer, J., Hegarty, J., Ashcroft, A., Frampton, C. M. A., & Barclay, M. L. (2016). The scratch test for identifying the lower liver edge is at least as accurate as percussion and is significantly more effective for young trainees: A randomised comparative trial. New Zealand Medical Journal, 129(1446), 53-63. Retrieved from http://www.nzma.org.nz/journal

Chambers, C. N. L., Frampton, C. M. A., Barclay, M., & McKee, M. (2016). Burnout prevalence in New Zealand's public hospital senior medical workforce: A cross-sectional mixed methods study. BMJ Open, 6(11), e013947. doi: 10.1136/bmjopen-2016-013947

McCombie, A., Langlotz, T., Barclay, M., Walmsley, R., Regenbrecht, H., & Schultz, M. (2016). Systematic review of IBD smartphone apps for symptom monitoring and communication with healthcare professionals. Journal of mHealth, 3(3), 36-41. Retrieved from http://www.thejournalofmhealth.com/

Huelsen, A., Oumer, R., Ashcroft, A., Roberts, R. H., Coulter, G. N., Kelly, S. J., & Barclay, M. L. (2016). Achalasia: A 13-year, single-centre experience comparing endoscopic balloon dilation and laparoscopic Heller myotomy. New Zealand Medical Journal, 129(1433), 45-54. Retrieved from http://www.nzma.org.nz/journal

Wright, D. F. B., Duffull, S. B., Merriman, T. R., Dalbeth, N., Barclay, M. L., & Stamp, L. K. (2016). Predicting allopurinol response in patients with gout. British Journal of Clinical Pharmacology, 81(2), 277-289. doi: 10.1111/bcp.12799

Hock, B. D., Stamp, L. K., Hayman, M. W., Keating, P. E., Helms, E. T. J., & Barclay, M. L. (2016). Development of an ELISA-based competitive binding assay for the analysis of drug concentration and anti-drug antibody levels in patients receiving adalimumab or infliximab. Therapeutic Drug Monitoring, 38(1), 32-41. doi: 10.1097/ftd.0000000000000229

Conference Contribution - Published proceedings: Abstract

Keating, P., Hock, B., Barclay, M., Stamp, L., Spellerberg, M., & O'Donnell, J. (2016). Application of an ELISA based competitive binding assay to measure concentration of anti-TNF biologics and neutralising anti-drug antibodies in the clinical laboratory. European Journal of Immunology, 46(Suppl. 1), (pp. 1033). doi: 10.1002/eji.201670200

Borrie, T. L., Morahan, M.-C., Barclay, M. L., Vella-Brincat, J. W. A., & McQueen, G. P. (2016). Comparison of enquiries for complementary and alternative medicines with enquiries for conventional medicines at the Medicines Information Service at Christchurch Hospital from 2010 to 2016. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Molecular Pharmacology of G Protein-Coupled Receptors (ASCEPT-MPGPCR) Joint Scientific Meeting. 534. Retrieved from http://www.asceptasm.com/

Hamilton, N., Barclay, M. L., & Doogue, M. P. (2016). Diagnosing and recording adverse drug reactions in general medical patients, a cross-sectional study. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Molecular Pharmacology of G Protein-Coupled Receptors (ASCEPT-MPGPCR) Joint Scientific Meeting. 419. Retrieved from http://www.asceptasm.com/

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2016). Predicting oxypurinol exposure in patients receiving intermittent haemodialysis. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 48). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Hamilton, N., Barclay, M. L., & Doogue, M. P. (2016). Diagnosing and recording adverse drug reactions in general medical patients: A cross-sectional study. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 30). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Barclay, M. L. (2016). Monitoring of monoclonal antibody drugs. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 24). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Chuah, Q., Vella-Brincat, J., Chin, P., Barclay, M., & Doogue, M. (2016). Use of clinical decision support in ePrescribing to facilitate generic prescribing. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 20). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Conference Contribution - Poster Presentation (not in published proceedings)

McCombie, A., Langlotz, T., Barclay, M., Walmsley, R., Regenbrecht, H., & Schultz, M. (2016, November). Systematic review of IBD smartphone apps for symptom monitoring and communication with healthcare professionals. Poster session presented at the New Zealand Society of Gastroenterology & New Zealand Nurses Organisation (NZNO) Gastroenterology Nurses Section Annual Scientific Meeting, Hamilton, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Stamp, L., Chapman, P., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2016, August). The safety and efficacy of allopurinol dose escalation in people with gout: A randomised controlled trial. Verbal presentation at the New Zealand Rheumatology Association Annual Scientific Meeting, Napier, New Zealand.

2015

Journal - Research Article

Roberts, R. L., & Barclay, M. L. (2015). Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics, 16(8), 891-903. doi: 10.2217/pgs.15.29

Chua, E. W., Cree, S., Barclay, M. L., Doudney, K., Lehnert, K., Aitchison, A., & Kennedy, M. A. (2015). Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers. Pharmacogenomics Journal, 15, 414-421. doi: 10.1038/tpj.2015.9

Doecke, J. D., Simms, L. A., Zhao, Z. Z., Roberts, R. L., Fowler, E. V., Croft, A., … Barclay, M. L., Merriman, T. R., Gearry, R. B., … Radford-Smith, G. L. (2015). Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease. Journal of Gastroenterology & Hepatology, 30(2), 299-307. doi: 10.1111/jgh.12674

Conference Contribution - Published proceedings: Abstract

McGowan, A., Jardine, D. L., Barclay, M. L., & Doogue, M. P. (2015). Complex patients, polypharmacy and guidelines. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 525. Retrieved from http://www.asceptasm.com/

Barclay, M. L., Jalilzadeh, A., Vajjah, P., & Duffull, S. (2015). A mathematical model of the metabolic pathway for azathioprine and 6-mercaptopurine. Proceedings of the Australasian Pharmaceutical Science Association and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (APSA-ASCEPT) Joint Scientific Meeting: Drugs to Medicines: Up Close and Personal. 158. Retrieved from http://www.asceptasm.com/

Kannangara, D., Graham, G., Wright, D., Barclay, M., Stamp, L., Williams, K., & Day, R. (2015). Treating gout patients with allopurinol: A concentration- or dose-response approach? Internal Medicine Journal, 45(Suppl. 2), (pp. 13). doi: 10.1111/imj.12752

Thompson, A., Roberts, S., Cheng, W., Angus, P., Visvanathan, K., Iyer, R., & Barclay, M. (2015). SB 9200, A novel immunomodulator for patients with viral hepatitis: Phase 1 MAD Study in patients with hepatitis C virus (HCV) infection. Journal of Hepatology, 62(Suppl. 2), (pp. S283-S284). doi: 10.1016/S0168-8278(15)30194-X

Wright, D. F. B., Duffull, S. B., Merriman, T. R., Barclay, M. L., & Stamp, L. K. (2015). Allopurinol dosing in patients with renal impairment. Proceedings of the Twenty-Fourth Annual Meeting of the Population Approach Group in Europe (PAGE). 3338. Retrieved from http://www.page-meeting.org/

Conference Contribution - Verbal presentation and other Conference outputs

Barclay, M. (2015, November). Anti-TNF levels and antibodies. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Section Annual Scientific Meeting, Rotorua, New Zealand.

Wright, D. F. B., Duffull, S. B., Merriman, T. R., Dalbeth, N., Barclay, M. L., & Stamp, L. K. (2015, September). Predicting allopurinol response in patients with renal impairment. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2014

Journal - Research Article

Pan, S., Stamp, L. K., Duffull, S. B., Barclay, M. L., Dalrymple, J. M., Drake, J., Zhang, M., & Korell, J. (2014). Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clinical Pharmacokinetics, 53(12), 1161-1170. doi: 10.1007/s40262-014-0179-5

Stamp, L. K., Merriman, T. R., Barclay, M. L., Singh, J. A., Roberts, R. L., Wright, D. F. B., & Dalbeth, N. (2014). Impaired response or insufficient dosage? Examining the potential causes of ”inadequate response” to allopurinol in the treatment of gout. Seminars in Arthritis & Rheumatism, 44(2), 170-174. doi: 10.1016/j.semarthrit.2014.05.007

Chin, P. K. L., Wright, D. F. B., Zhang, M., Wallace, M. C., Roberts, R. L., Patterson, D. M., Jensen, B. P., Barclay, M. L., & Begg, E. J. (2014). Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs in R&D, 14(2), 113-123. doi: 10.1007/s40268-014-0045-9

Chin, P. K. L., Patterson, D. M., Zhang, M., Jensen, B. P., Wright, D. F. B., Barclay, M. L., & Begg, E. J. (2014). Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. British Journal of Clinical Pharmacology, 78(3), 630-638. doi: 10.1111/bcp.12366

Buffery, P. J., Allen, K. M., Chin, P. K. L., Moore, G. A., Barclay, M. L., & Begg, E. J. (2014). Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: Can the strategy be improved? Therapeutic Drug Monitoring, 36(1), 86-92. doi: 10.1097/FTD.0b013e31829dc940

Stamp, L. K., & Barclay, M. (2014). Therapeutic drug monitoring in rheumatic diseases: Utile or futile? Rheumatology, 53(6), 988-997. doi: 10.1093/rheumatology/ket355

Korell, J., Duffull, S. B., Dalrymple, J. M., Drake, J., Zhang, M., Barclay, M. L., & Stamp, L. K. (2014). Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. British Journal of Clinical Pharmacology, 77(3), 493-497. doi: 10.1111/bcp.12209

Journal - Research Other

Roberts, R. L., Wallace, M. C., Seinen, M. L., Krishnaprasad, K., Chew, A., Lawrance, I., … Barclay, M. L. (2014). PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. American Journal of Gastroenterology, 109, 925-927. doi: 10.1038/ajg.2014.89

Conference Contribution - Published proceedings: Abstract

Wright, D. F. B., Merriman, T. R., Duffull, S. B., Barclay, M. L., & Stamp, L. K. (2014). The relationship between fractional urate clearance and renal transporter genotype in patients with gout. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) Joint Scientific Meeting. (pp. 47). Retrieved from http://www.asceptasm.com/

Barclay, M. L., Helms, E., Hock, B., Schultz, M., & Stamp, L. K. (2014). Trough concentrations of infliximab and adalimumab, and anti-drug antibodies, correlate with drug response in inflammatory bowel disease. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) Joint Scientific Meeting. (pp. 25). Retrieved from http://www.asceptasm.com/

Conference Contribution - Poster Presentation (not in published proceedings)

Su, H., Sutharshan, K., Hodgins, C., Dobbs, B., Falvey, J., & Barclay, M. L. (2014, November). Water-perfusion versus high-resolution solid state oesophageal manometry: A retrospective study of 832 cases. Poster session presented at the New Zealand Society of Gastroenterology & New Zealand Nurses Organisation Gastroenterology Section Annual Scientific Meeting, Auckland, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Barclay, M. (2014, November). Mathematical model of the thiopurine metabolic pathway incorporating pharmacogenetics. Verbal presentation at the 10th Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Ho, C., Walmsley, R., Gray, A., Langlotz, T., Regenbrecht, H., Barclay, M., & Schultz, M. (2014, November). IBDsmart: The usability and acceptance of mobile media in the monitoring of patients with IBD. Verbal presentation at the New Zealand Society of Gastroenterology & New Zealand Nurses Organisation Gastroenterology Section Annual Scientific Meeting, Auckland, New Zealand.

Barclay, M. L., Helms, E., Hock, B., Stamp, L. K., & Schultz, M. (2014, November). Infliximab and adalimumab trough concentrations and anti-drug antibodies correlate with response in inflammatory bowel disease. Verbal presentation at the New Zealand Society of Gastroenterology & New Zealand Nurses Organisation Gastroenterology Section Annual Scientific Meeting, Auckland, New Zealand.

Barclay, M. (2014, August). Infliximab and adalimumab trough concentrations and anti-drug antibodies correlate with response in inflammatory bowel disease. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2013

Journal - Research Article

Van Egmond, R., Barclay, M. L., Chin, P. K. L., Sies, C. W., & Florkowski, C. M. (2013). Biological variation of thiopurine methyltransferase enzyme activity: When has a significant change taken place? Annals of Clinical Biochemistry, 50(5), 473-478. doi: 10.1177/0004563212473441

International Multiple Sclerosis Genetic Consortium (IMSGC), and also Mason, D., Barclay, M., Roberts, R., & Gearry, R. (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 45(11), 1353-1360. doi: 10.1038/ng.2770

Beaudoin, M., Goyette, P., Boucher, G., Lo, K. S., Rivas, M. A., Stevens, C., … and also Barclay, M., Gearry, R., & Roberts, R. (2013). Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genetics, 9(9), e1003723. doi: 10.1371/journal.pgen.1003723

Falvey, J. D., Bentley, R. W., Merriman, T. R., Hampton, M. B., Barclay, M. L., Gearry, R. B., & Roberts, R. L. (2013). Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis. World Journal of Gastroenterology, 19(39), 6656-6664. doi: 10.3748/wjg.v19.i39.6656

Nasir, B. F., Griffiths, L. R., Nasir, A., Roberts, R., Barclay, M., Gearry, R. B., & Lea, R. A. (2013). An envirogenomic signature is associated with risk of IBD-related surgery in a population-based Crohn’s disease cohort. Journal of Gastrointestinal Surgery, 17(9), 1643-1650. doi: 10.1007/s11605-013-2250-1

Chin, P. K. L., Vella-Brincat, J. W. A., Walker, S. L., Barclay, M. L., & Begg, E. J. (2013). Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Internal Medicine Journal, 43(7), 778-783. doi: 10.1111/imj.12170

Wright, D. F. B., Stamp, L. K., Merriman, T. R., Barclay, M. L., Duffull, S. B., & Holford, N. H. G. (2013). The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European Journal of Clinical Pharmacology, 69(7), 1411-1421. doi: 10.1007/s00228-013-1478-8

Korell, J., Stamp, L. K., Barclay, M. L., Dalrymple, J. M., Drake, J., Zhang, M., & Duffull, S. B. (2013). A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clinical Pharmacokinetics, 52(6), 475-485. doi: 10.1007/s40262-013-0052-y

Koning, M., Ailabouni, R., Gearry, R. B., Frampton, C. M. A., & Barclay, M. L. (2013). Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: A population-based, case-control study. Inflammatory Bowel Diseases, 19(4), 767-778. doi: 10.1097/MIB.0b013e31827f27c8

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2013). A simple high-performance liquid chromatography method for simultaneous determination of three triazole antifungals in human plasma. Antimicrobial Agents & Chemotherapy, 57(1), 484-489. doi: 10.1128/aac.00768-12

Nasir, B. F., Griffiths, L., Nasir, A., Roberts, R., Barclay, M., Gearry, R., & Lea, R. A. (2013). Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. Journal of Clinical Gastroenterology, 47(3), 242-245. doi: 10.1097/MCG.0b013e318258314d

Journal - Research Other

Chin, P. K. L., Barclay, M. L., & Begg, E. J. (2013). Rifampicin and dabigatran etexilate: A place for laboratory coagulation monitoring. British Journal of Clinical Pharmacology, 75(2), 554-555. doi: 10.1111/j.1365-2125.2012.04408.x

Conference Contribution - Published proceedings: Abstract

Huelsen, A., Fischer, J., Hegarty, J., Lim, J. Y., Burnside, M. J., Karim, S. N., Onyango, N., Frampton, C., Spencer, A. J., & Barclay, M. L. (2013). The scratch test for identifying the lower liver edge is at least as accurate as percussion and is more effective for young trainees: A randomised controlled study. Internal Medicine Journal, 43(Suppl. 3), (pp. 16). doi: 10.1111/imj.12149

Conference Contribution - Verbal presentation and other Conference outputs

Kennedy, M. A., Chua, E. W., Macmil, S., Foulds, J., Barclay, M., Savage, R., … Miller, A. (2013, August). Genomic medicine and adverse drug reactions. Verbal presentation at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.

Jalilzadeh, A., Barclay, M., Vajjah, P., & Duffull, S. (2013, August). A systems pharmacology model to individualise azathioprine and 6MP dosing. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

Chua, E. W., Macmil, S., Foulds, J., Barclay, M., Savage, R., Helsby, N. A., Miller, A., & Kennedy, M. A. (2013, August). Understanding adverse Drug Reactions or responses Using Genomic Sequencing (UDRUGS). Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

Walter, C., Gow, C., Chin, P. K., & Barclay, M. L. (2013, August). All intensive care unit patients on phenytoin require measurement of free drug concentration due to reduced plasma protein binding. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

Buffery, P. J., Barclay, M. L., Doogue, M. P., Moore, G. A., & Kennedy, M. A. (2013, August). Codeine, breastfeeding and infant narcosis: A cautionary case. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

Stebbings, S., Butt, G., & Barclay, M. (2013, June). The big idea. Panel discussion at the University of Otago Gut Health Network Research Theme Meeting, Dunedin, New Zealand.

2012

Journal - Research Article

Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., … Gearry, R., … and also Barclay, M., & Roberts, R. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119-124. doi: 10.1038/nature11582

Eglinton, T. W., Barclay, M. L., Gearry, R. B., & Frizelle, F. A. (2012). The spectrum of perianal Crohn's disease in a population-based cohort. Diseases of the Colon & Rectum, 55(7), 773-777. doi: 10.1097/DCR.0b013e31825228b0

Zhang, M., Moore, G. A., Fernyhough, L. J., Barclay, M. L., & Begg, E. J. (2012). Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical & Bioanalytical Chemistry, 404(6-7), 2091-2096. doi: 10.1007/s00216-012-6284-0

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2012). Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: Implications for clinical practice. Rheumatology, 51(9), 1670-1676. doi: 10.1093/rheumatology/kes091

Roberts, R. L., & Barclay, M. L. (2012). Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. Journal of Gastroenterology & Hepatology, 27(10), 1546-1554. doi: 10.1111/j.1440-1746.2012.07220.x

Van Egmond, R., Chin, P., Zhang, M., Sies, C. W., & Barclay, M. L. (2012). High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Alimentary Pharmacology & Therapeutics, 35(10), 1181-1189. doi: 10.1111/j.1365-2036.2012.05084.x

Eglinton, T. W., Roberts, R., Pearson, J., Barclay, M., Merriman, T. R., Frizelle, F. A., & Gearry, R. B. (2012). Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort. American Journal of Gastroenterology, 107, 589-596. doi: 10.1038/ajg.2011.437

Roberts, R. L., Gallo, L.-M. D., Barclay, M. L., Gómez-García, M., Cardeña, C., Merriman, T. R., Gearry, R. B., & Martin, J. (2012). Independent replication of an association of CNVR7113.6 with Crohn's disease in caucasians. Inflammatory Bowel Diseases, 18(2), 305-311. doi: 10.1002/ibd.21752

Journal - Research Other

Chin, P. K. L., Vella-Brincat, J. W. A., Barclay, M. L., & Begg, E. J. (2012). Perspective on dabigatran etexilate dosing: Why not follow standard pharmacological principles? British Journal of Clinical Pharmacology, 74(5), 734-740. doi: 10.1111/j.1365-2125.2012.04266.x

Conference Contribution - Published proceedings: Abstract

Huelsen, A., Fischer, J., Hegarty, J., Lim, J. Y., Burnside, M. J., Karim, S. N., Onyango, N., Frampton, C., Spencer, A. J., & Barclay, M. L. (2012). The Scratch Test for identifying the lower liver edge is at least as accurate as percussion and is more effective for trainees: A randomized controlled study. New Zealand Medical Journal, 125(1367). Retrieved from http://www.nzma.org.nz/journal

Wright, D. F. B., Stamp, L. K., Merriman, T. R., Barclay, M. L., Duffull, S. B., & Holford, N. H. G. (2012). The population pharmacokinetics of allopurinol and oxypurinol. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australasian Pharmaceutical Science Association (APSA) Joint Conference: Medication Safety. (pp. 55). Retrieved from http://www.ascept-apsa.com/

Chin, P. K. L., Barclay, M. L., & Begg, E. J. (2012). Dose individualisation of Dabigatrin. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australasian Pharmaceutical Science Association (APSA) Joint Conference: Medication Safety. (pp. 33). Retrieved from http://www.ascept-apsa.com/

Barclay, M. L. (2012). Practical experiences of 3 decades of TDM/TCI in Christchurch. Proceedings of the Medical Sciences Congress (MedSci). (pp. 7). Retrieved from http://www.medscinz.co.nz/QRW2012%20MedSci%20Abstracts.pdf

Conference Contribution - Verbal presentation and other Conference outputs

Chin, P. K. L., Barclay, M. L., & Begg, E. J. (2012, November). Dabigatrin oral availability: Role of P-glycoprotein. Verbal presentation at the 8th Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Barclay, M. (2012, November). Pharmacogenetics of TNF-alpha blockers. Verbal presentation at the 8th Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Kennedy, M. A., Chua, E. W., Barclay, M. L., & Savage, R. (2012, November). Growing a New Zealand biobank (UDRUGS) to allow genetic analysis of rare, serious adverse drug reactions and unusual drug responses. Verbal presentation at the 8th Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Walmsley, R., Coppell, K., Griffin, F., Barclay, M., & Stamp, L. (2012, June). Who are we (Part III). Panel discussion at the Inaugural GutHealth Network Workshop, Dunedin, New Zealand.

2011

Journal - Research Article

Rossin, E. J., Lage, K., Raychaudhuri, S., Xavier, R. J., Tatar, D., Benita, Y., International Inflammatory Bowel Disease Genetics Constortium, including Roberts, R., Barclay, M., Gearry, R., … Daly, M. J. (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genetics, 7(1), e1001273. doi: 10.1371/journal.pgen.1001273

Rivas, M. A., Beaudoin, M., Gardet, A., Stevens, C., Sharma, Y., Zhang, C. K., … International Inflammatory Bowel Disease Genetics Consortium, including Barclay, M., Gearry, R., Roberts, R., … Daly, M. J. (2011). Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nature Genetics, 43(11), 1066-1073. doi: 10.1038/ng.952

Diaz-Gallo, L.-M., Espino-Paisán, L., Fransen, K., Gómez-García, M., van Sommeren, S., Cardeña, C., … Barclay, M. L., … Gearry, R. B., Roberts, R. L., … Merriman, T. R., … Martin, J. (2011). Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases, 17(11), 2287-2294. doi: 10.1002/ibd.21630

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Journal of Rheumatology, 38(12), 2540-2547. doi: 10.3899/jrheum.110481

Morgan, A. R., Han, D.-Y., Lam, W.-J., Triggs, C. M., Fraser, A. G., Barclay, M., Gearry, R. B., … Ferguson, L. R. (2011). Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Human Immunology, 72, 1117-1127. doi: 10.1016/j.humimm.2011.08.011

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Relationship between serum urate and plasma oxypurinol in the management of gout: Determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clinical Pharmacology & Therapeutics, 90(3), 392-398. doi: 10.1038/clpt.2011.113

Glubb, D. M., Gearry, R. B., Barclay, M. L., Roberts, R. L., Pearson, J., Keenan, J. I., McKenzie, J., & Bentley, R. W. (2011). NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World Journal of Gastroenterology, 17(23), 2829-2837. doi: 10.3748/wjg.v17.i23.2829

Anderson, C. A., Boucher, G., Lees, C. W., Franke, A., D’Amato, M., Taylor, K. D., … Barclay, M., … Roberts, R., … Gearry, R., … Rioux, J. D. (2011). Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 43(3), 246-254. doi: 10.1038/ng.764

Roberts, R. L., Hollis-Moffatt, J. E., Gómez-García, M., Fransen, K., Ponsioen, C. Y., Crusius, B. A., … Merriman, T. R., Barclay, M. L., Gearry, R. B., & Alizadeh, B. Z. (2011). Association of the protein-tyrosine phosphatase nonreceptor type substrate 1 (PTPNS1) gene with inflammatory bowel disease. Inflammatory Bowel Diseases, 17(2), E19-E21. doi: 10.1002/ibd.21470

Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., Ross, A. G., Stedman, C. A. M., … Barclay, M. L. (2011). Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology & Hepatology, 26(1), 49-54. doi: 10.1111/j.1440-1746.2010.06489.x

Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2011). Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including in those with renal impairment. Arthritis & Rheumatism, 63(2), 412-421. doi: 10.1002/art.30119

Journal - Research Other

Vella-Brincat, J., McKean, A., & Barclay, M. (2011). Clozapine-induced gastrointestinal hypomotility [Letter]. Australasian Psychiatry, 19(5), 450-451. doi: 10.3109/10398562.2011.610462

Journal - Professional & Other Non-Research Articles

Bentley, R. W., Keown, D., Merriman, T. R., Krishnan, M. R., Gearry, R. B., Barclay, M. L., Roberts, R. L., & Day, A. S. (2011). Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males [Letter to the editor]. Alimentary Pharmacology & Therapeutics, 33(7), 855-856. doi: 10.1111/j.1365-2036.2011.04588.x

Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Van Egmond, R., Chin, P. K. L., & Mulder, C. J. J. (2011). High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 7.4. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2011). Determination of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in human red blood cells by LC-MS/MS. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 7.2. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Buffery, P., Begg, E., Barclay, M., & Moore, G. (2011). A retrospective pharmacokinetic review of the busulphan monitoring service at Christchurch Hospital. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and Carney Symposium: New Zealand Annual Scientific Meeting. 4.5. Retrieved from http://www.otago.ac.nz/asceptnz/docs/programme.pdf

Eglinton, T. W., Roberts, R. L., Pearson, J. F., Barclay, M. L., Ferguson, L. R., Han, D. Y., Frizelle, F. A., & Gearry, R. B. (2011). Clinical and genetic risk factors for perianal Crohn's disease (CD) in a population based cohort. Colorectal Disease, 13(Suppl. s5), 067, (pp. 12). doi: 10.1111/j.1463-1318.2011.02655.x

Diaz-Gallo, L.-M., Espino-Paisán, L., Fransen, K., Gómez-García, M., van Sommeren, S., Cardeña, C., … Barclay, M. L., … Gearry, R. B., Roberts, R. L., … Merriman, T. R., … Martin, J. (2011). Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Journal of Translational Medicine, 8(Suppl. 1), P2. doi: 10.1186/1479-5876-8-S1-P2

Stamp, L. K., Chapman, P. T., Barclay, M., Kremer, J. M., & Dervieux, T. (2011). Red blood cell folate polyglutamates are an important determinant of RA disease activity in patients on Methotrexate: Implications for folic acid supplementation. Arthritis & Rheumatism, 63(Suppl. 10), (pp. S961-S962). doi: 10.1002/art.33310

Conference Contribution - Poster Presentation (not in published proceedings)

Eglinton, T. W., Roberts, R. L., Pearson, J., Ferguson, L., Han, D., Barclay, M. L., Frizelle, F. A., & Gearry, R. B. (2011, November). Clinical and genetic risk factors for Perianal Crohn's disease (CD) in a population based cohort. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Dunedin, New Zealand.

Eglinton, T. W., Barclay, M. L., Frizelle, F. A., & Gearry, R. B. (2011, November). The spectrum of Perianal Crohn's disease in a population based cohort. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Dunedin, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Roberts, R., Zhang, M., Gearry, R. B., & Barclay, M. L. (2011, October). Non-synonymous single nucleotide polymorphisms in guanosine 5'-monophosphate synthetase associated with altered metabolism of azathioprine. Verbal presentation at the 19th United European Gastroenterology Week (UEGW), Stockholm, Sweden.

Roberts, R., Gearry, R. B., Barclay, M. L., Hollis-Moffatt, J. E., Merriman, T. R., Highton, J., Jenks, K., Harrison, A. A., & Stebbings, S. M. (2011, October). Specific Interleukin 23 receptor haplotype may confer protection against Crohn's disease while increasing risk of spondyloarthritis. Verbal presentation at the 19th United European Gastroenterology Week (UEGW), Stockholm, Sweden.

2010

Journal - Research Article

Weersma, R. K., Crusius, J. B. A., Roberts, R. L., Koeleman, B. P. C., Palomino-Morales, R., Wolfkamp, S., Hollis-Moffatt, J. E., … Gearry, R. B., Barclay, M. L., … Merriman, T. R., … Alizadeh, B. Z. (2010). Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations. Inflammatory Bowel Diseases, 16(12), 2080-2089. doi: 10.1002/ibd.21342

Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., … Roberts, R., … Barclay, M., … Gearry, R., … Parkes, M. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 42(12), 1118-1125. doi: 10.1038/ng.717

Stewart, L. C., Day, A. S., Pearson, J., Barclay, M. L., Gearry, R. B., Roberts, R. L., & Bentley, R. W. (2010). SLC11A1 polymorphisms in inflammatory bowel disease and Mycobacterium avium subspecies paratuberculosis status. World Journal of Gastroenterology, 16(45), 5727-5731. doi: 10.3748/wjg.v16.i45.5727

Ngu, J. H., Bechly, K., Chapman, B. A., Burt, M. J., Barclay, M. L., Gearry, R. B., & Stedman, C. A. M. (2010). Population-based epidemiology study of autoimmune hepatitis: A disease of older women? Journal of Gastroenterology & Hepatology, 25(10), 1681-1686. doi: 10.1111/j.1440-1746.2010.06384.x

Eglinton, T., Reilly, M., Chang, C., Barclay, M., Frizelle, F., & Gearry, R. (2010). Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. British Journal of Surgery, 97(7), 1103-1109. doi: 10.1002/bjs.7031

Schultz, M., Gearry, R., Walmsley, R., Day, A. S., Fraser, A., Wyeth, J., Barclay, M., … Whiteside, C. (2010). New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease. New Zealand Medical Journal, 123(1314). Retrieved from http://journal.nzma.org.nz/journal/123-1314/4115/content.pdf

Simms, L. A., Doecke, J. D., Roberts, R. L., Fowler, E. V., Zhao, Z. Z., McGuckin, M. A., … McCallum, R., … Barclay, M. L., Gearry, R. B., Merriman, T. R., … Radford-Smith, G. L. (2010). KCNN4 gene variant is associated with ileal Crohn's disease in the Australian and New Zealand population. American Journal of Gastroenterology, 105, 2209-2217. doi: 10.1038/ajg.2010.161

Bentley, R. W., Cleynen, I., Gearry, R. B., Barclay, M. L., Rutgeerts, P., Merriman, T. R., … Roberts, R. L., & Vermeire, S. (2010). Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. Genes & Immunity, 11, 509-514. doi: 10.1038/gene.2010.15

Stamp, L. K., Chapman, P. T., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., Kennedy, M. A., & Roberts, R. L. (2010). Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics & Genomics, 20(6), 367-376. doi: 10.1097/FPC.0b013e3283398a71

Triggs, C. M., Munday, K., Hu, R., Fraser, A. G., Gearry, R. B., Barclay, M. L., & Ferguson, L. R. (2010). Dietary factors in chronic inflammation: Food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutation Research: Fundamental & Molecular Mechanisms of Mutagenesis, 690, 123-138. doi: 10.1016/j.mrfmmm.2010.01.020

Roberts, R. L., Topless, R. K. G., Phipps-Green, A. J., Gearry, R. B., Barclay, M. L., & Merriman, T. R. (2010). Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes & Immunity, 11, 351-356. doi: 10.1038/gene.2010.11

Bentley, R. W., Pearson, J., Gearry, R. B., Barclay, M. L., McKinney, C., Merriman, T. R., & Roberts, R. L. (2010). Association of higher DEFB4 genomic copy number with Crohn's disease. American Journal of Gastroenterology, 105(2), 354-359. doi: 10.1038/ajg.2009.582

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., & Barclay, M. L. (2010). Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis & Rheumatism, 62(2), 359-368. doi: 10.1002/art.27201

Gearry, R. B., Richardson, A. K., Frampton, C. M., Dodgshun, A. J., & Barclay, M. L. (2010). Population-based cases control study of inflammatory bowel disease risk factors. Journal of Gastroenterology & Hepatology, 25, 325-333. doi: 10.1111/j.1440-1746.2009.06140.x

Journal - Research Other

Roberts, R. L., Gearry, R. B., & Barclay, M. L. (2010). Allopurinol—thiopurine combination therapy in inflammatory bowel disease: Are there genetic clues to this puzzle? [Editorial]. Pharmacogenomics, 11(11), 1505-1508. doi: 10.2217/pgs.10.143

Stamp, L. K., O'Donnell, J. L., Barclay, M. L., Frampton, C., & Chapman, P. T. (2010). Response to comments [Letter to the editor]. Arthritis & Rheumatism, 62(8), 2560-2561. doi: 10.1002/art.27539

Hollis-Moffatt, J. E., Gearry, R. B., Barclay, M. L., Merriman, T. R., & Roberts, R. L. (2010). Consolidation of evidence for association of the KIAA1109-TENR-IL2-IL21 rs6822844 variant with Crohn's disease [Letter]. American Journal of Gastroenterology, 105(5), 1204-1205. doi: 10.1038/ajg.2010.34

Gearry, R. B., Day, A. S., Barclay, M. L., Leong, R. W. L., & Sparrow, M. P. (2010). Azathioprine and allopurinol: A two-edged interaction [Editorial]. Journal of Gastroenterology & Hepatology, 25(4), 653-655. doi: 10.1111/j.1440-1746.2010.06254.x

Conference Contribution - Published proceedings: Abstract

Stamp, L. K., O'Donnell, J. L., Chapman, P., Zhang, M., James, J., Frampton, C., & Barclay, M. (2010). The effect on MTX polyglutamate concentration profile after changing from oral to subcutaneous methotrexate in rheumatoid arthritis. Arthritis & Rheumatism, 62(Suppl. 10). doi: 10.1002/art.30166

Gearry, R. B., Glubb, D. M., Hollis-Moffatt, J. E., Topless, R. K. G., Simms, L. A., Doecke, J. D., … Barclay, M. L., … Merriman, T. R., … Roberts, R. L. (2010). Extracellular matrix protein 1 is associated with ulcerative colitis but is not implicated in Crohn's disease. Journal of Gastroenterology & Hepatology, 25(Suppl. 3), (pp. A80). doi: 10.1111/j.1440-1746.2010.06454.x

Doecke, J., Simms, L. A., Zhao, Z. Z., Huang, N., Hanigan, K., Croft, A., … Roberts, R. L., … Barclay, M. L., … Gearry, R. B., … Radford-Smith, G. L. (2010). Genetic susceptibility in IBD: Overlap between ulcerative colitis and Crohn's disease. Journal of Gastroenterology & Hepatology, 25(Suppl. 3), (pp. A84). doi: 10.1111/j.1440-1746.2010.06454.x

Simms, L. A., Doecke, J., Huang, N., Zhao, Z. Z., Kristine, F. U., Roberts, R. L., Barclay, M. L., … Gearry, R. B., & Radford-Smith, G. L. (2010). Genotype markers predict time to first resection in Crohn's disease patients. Journal of Gastroenterology & Hepatology, 25(Suppl. 3), (pp. A82-A83). doi: 10.1111/j.1440-1746.2010.06454.x

Roberts, R. L., Gearry, R. B., Barclay, M. L., Hollis-Moffatt, J. E., Merriman, T. R., Jenks, K., Schultz, M., & Stebbings, S. (2010). Specific Interleukin-23 receptor haplotype may confer protection against Crohn's disease while increasing risk of Spondyloarthritis. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf

Glubb, D. M., Pearson, J., Hollis-Moffatt, J. E., Topless, R. K. G., Merriman, T. R., Simms, L. A., … Barclay, M. L., … Gearry, R. B., … Roberts, R. L. (2010). Extracellular Matrix Protein 1 is associated with ulcerative colitis but is not implicated in Crohn's disease. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf

Huelsen, A., & Barclay, M. L. (2010). Balloon dilatation in achalasia is effective and safe: A 13-year single centre experience. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf

Falvey, J. D., Bentley, R. W., Merriman, T. R., Hampton, M. B., Barclay, M. L., Gearry, R. B., & Roberts, R. L. (2010). Gene-gene interaction between Macrophage Migration Inhibitory Factor (MIF) and NOD2 alters susceptibility to ileal Crohn's disease. New Zealand Medical Journal, 123(1327). Retrieved from http://journal.nzma.org.nz/journal/123-1327/4492/content.pdf

Ngu, J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2010). Primary biliary cirrhosis in Canterbury, New Zealand: A population-based study. Journal of Gastroenterology and Hepatology. 25(Suppl. 2), (pp. A11). doi: 10.1111/j.1440-1746.2009.06462.x

Ngu, J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2010). Population-based epidemiology of primary sclerosing cholangitis in Canterbury, New Zealand. Journal of Gastroenterology and Hepatology. 25(Suppl. 2), (pp. A11). doi: 10.1111/j.1440-1746.2009.06462.x

Roberts, R. L., Gearry, R. B., & Barclay, M. L. (2010). Are there pharmacogenetic indicators for allopurinol combination therapy in inflammatory bowel disease? Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Stamp, L. K., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., & Chapman, P. T. (2010). Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Barclay, M. L., Stamp, L. K., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2010). Effects of changing from oral to subcutaneous administration of methotrexate on RBC MTX polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting and the 6th Annual Carney Pharmacogenomics Symposium. ASCEPT. Retrieved from http://www.ascept.org.nz/

Conference Contribution - Verbal presentation and other Conference outputs

Barclay, M. (2010, May). Managing azathioprine. Verbal presentation at the New Zealand Dermatological Society & the Dowling Club Combined Annual Meeting, Christchurch, New Zealand.

Roberts, R., Gearry, R., Barclay, M., Hollis-Moffatt, J., Merriman, T., & Jenks, K. (2010, August). Specific Interleukin 23 receptor haplotype may confer protection against intestinal inflammation while increasing risk of joint inflammation in spondyloarthritis. Verbal presentation at the New Zealand Rheumatology Association Annual Scientific Meeting, Christchurch, New Zealand.

2009

Journal - Research Article

Ferguson, L. R., Han, D. Y., Huebner, C., Petermann, I., Barclay, M. L., Gearry, R. B., … Demmers, P. S. (2009). Tumor necrosis factor receptor superfamily, member 1B haplotypes increase or decrease the risk of inflammatory bowel diseases in a New Zealand Caucasian population. Gastroenterology Research & Practice, 591704. doi: 10.1155/2009/591704

Huebner, C., Ferguson, L. R., Han, D. Y., Philpott, M., Barclay, M. L., Gearry, R. B., & et al (2009). Nucleotide-binding oligomerization domain containing I (NODI) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand Caucasian population: A case-control study. BMC Research Notes, 2, 52. doi: 10.1186/1756-0500-2-52

Petermann, I., Huebner, C., Browning, B. L., Gearry, R. B., Barclay, M. L., Kennedy, M., Roberts, R., … Han, D. Y., & Ferguson, L. R. (2009). Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Human Immunology, 70, 440-446. doi: 10.1016/j.humimm.2009.03.002

Huebner, C., Browning, B. L., Petermann, I., Han, D. Y., Philpott, M., Barclay, M., Gearry, R., … Ferguson, L. R. (2009). Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflammatory Bowel Diseases, 15(12), 1784-1793. doi: 10.1002/ibd.21019

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2009). Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B, 877(27), 3025-3030. doi: 10.1016/j.jchromb.2009.07.021

Petermann, I., Triggs, C. M., Huebner, C., Han, D. Y., Gearry, R. B., Barclay, M. L., … Ferguson, L. R. (2009). Mushroom intolerance: A novel diet-gene interaction in Crohn's disease. British Journal of Nutrition, 102(4), 506-508. doi: 10.1017/s0007114509276446

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., James, J., & Barclay, M. L. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis & Rheumatism, 60(8), 2248-2256. doi: 10.1002/art.24653

Journal - Research Other

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Barclay, M. L., Kennedy, M. A., Frampton, C. M. A., & Roberts, R. L. (2009). Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to longterm therapy with methotrexate response in rheumatoid arthritis [Letter]. Annals of the Rheumatic Diseases, 68(1), 154-155. doi: 10.1136/ard.2008.089383

Conference Contribution - Published proceedings: Abstract

Roberts, R. L., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., Kennedy, M. A., Barclay, M. L., & Stamp, L. K. (2009). Genetic polymorphisms in the folate pathway predict red blood cell folate concentrations but not methotrexate response in rheumatoid arthritis. Proceedings of the 5th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.otago.ac.nz/christchurch/otago019049.pdf

Glubb, D. M., Hollis-Moffatt, J. E., Topless, R. K. G., Gearry, R. B., . . ., Barclay, M. L., … Merriman, T. R., … Roberts, R. L. (2009). Extracellular Matrix Protein 1 is associated with ulcerative colitis but is not implicated in Crohn's disease. Proceedings of the GASTRO Conference. Retrieved from http://www.gastro2009.org/scien_prog/search.php?navId=244

Bentley, R. W., Pearson, J., Gearry, R. B., Barclay, M. L., McKinney, C., Merriman, T. R., & Roberts, R. L. (2009). Association of increased beta-defensin 2 genomic copy number with Crohn's disease. Proceedings of the GASTRO Conference. Retrieved from http://www.gastro2009.org/scien_prog/search.php?navId=244

Bentley, R. W., Cleynen, I., Gearry, R. B., Barclay, M. L., Rutgeerts, P., Merriman, T. R., … Roberts, R. L., & Vermeire, S. (2009). Meta-analysis provides no evidence for glioma-associated oncogene homolog 1 as a risk factor for inflammatory bowel disease in Caucasians. Proceedings of the GASTRO Conference. Retrieved from http://www.gastro2009.org/scien_prog/search.php?navId=244

Stamp, L., O'Donnell, J. L., Zhang, M., Frampton, C., Barclay, M., & Chapman, P. T. (2009). Increasing allopurinol dose above the recommended range is effective and safe in chronic gout, including in those with renal impairment: A pilot study. Arthritis & Rheumatism, 60(Suppl. 10), (pp. S729). doi: 10.1002/art.27423

Stamp, L., O'Donnell, J. L., Zhang, M., Frampton, C., Chapman, P. T., & Barclay, M. (2009). Relationship between serum urate and plasma oxypurinol: Is there a target plasma oxypurinol concentration to achieve serum urate ≤6mg/dL. Arthritis & Rheumatism, 60(Suppl. 10), (pp. S561). doi: 10.1002/art.27423

Stamp, L., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., Barclay, M., Kennedy, M., & Roberts, R. (2009). Functional polymorphisms within the folate pathway predict red blood cell folate concentrations but are not associated with methotrexate response in RA. Arthritis & Rheumatism, 60(Suppl. 10), (pp. S150). doi: 10.1002/art.27423

Barclay, M. L., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., & James, J. (2009). Determinants of red blood cell methotrexate polyglutamate concentrations in patients with rheumatoid arthritis on long-term methotrexate. In D. Hay & S. Ngo (Eds.), Proceedings of the 43rd Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 14. ASCEPT. [Abstract]

Barclay, M. L., Roberts, R. L., & Gearry, R. B. (2009). Using genetics of inflammatory bowel disease to develop new treatments: A different slant on pharmacogenetics. Proceedings of the 5th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.otago.ac.nz/christchurch/otago019049.pdf

Stamp, L. K., O'Donnell, J. L., Zhang, M., Frampton, C., James, J., Barclay, M., & Chapman, P. T. (2009). Relationship between allopurinol dose, plasma oxypurinol concentration and serum urate. Internal Medicine Journal, 39(Suppl. 2), (pp. A43). doi: 10.1111/j.1445-5994.2009.01951_1.x

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., James, J., & Barclay, M. L. (2009). Determinants of methotrexate red blood cell polyglutamates in patients with rheumatoid arthritis on long-term MTX. Internal Medicine Journal, 39(Suppl. 2), (pp. A43). doi: 10.1111/j.1445-5994.2009.01951_1.x

Conference Contribution - Poster Presentation (not in published proceedings)

Ngu, J. J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2009, November). Primary sclerosing cholangitis in Canterbury: High incidence and prevalence with reduced life expectancy. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Wellington, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Ngu, J. J. H., Wright, A., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2009, November). Population-based epidemiology of primary biliary cirrhosis in Canterbury, New Zealand. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Wellington, New Zealand.

Ngu, J. J. H., Bechly, K., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2009, November). Population-based epidemiology study of autoimmune hepatitis: A disease of older women? Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Wellington, New Zealand.

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2009, September). Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/ tandem mass spectrometry. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting, Dunedin, New Zealand.

Roberts, R. L., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., Kennedy, M. A., Barclay, M. L., & Stamp, L. K. (2009, September). Genetic polymorphisms in the folate pathway are predictive of red blood cell folate concentrations but not methotrexate response in rheumatoid arthritis patients. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting, Dunedin, New Zealand.

Barclay, M. L., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., Frampton, C., & James, J. (2009, September). Determinants of red blood cell methotrexate polyglutamate concentrations in patients with rheumatoid arthritis on long-term MTX. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting, Dunedin, New Zealand.

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C., & Barclay, M. L. (2009, September). Methotrexate polygutamate concentrations are not associated with disease control or toxicity in rheumatoid arthritis patients on long-term MTX. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting, Dunedin, New Zealand.

2008

Chapter in Book - Other

Frizelle, F., & Barclay, M. (2008). Constipation in adults. In C. Young (Ed.), Clinical evidence handbook: The international source of the best available evidence for effective health care. (pp. 167). UK: BMJ: Evidence Centre.

Journal - Research Article

Ferguson, L. R., Huebner, C., Petermann, I., Gearry, R. B., Barclay, M. L., Demmers, P., … Han, D. Y. (2008). Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World Journal of Gastroenterology, 14(29), 4652-4661. doi: 10.3748/wjg.14.4652

Dalrymple, J. M., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., & Barclay, M. L. (2008). Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism, 58(11), 3299-3308.

Ferguson, L. R., Browning, B. L., Huebner, C., Petermann, I., Shelling, A. N., Demmers, P., … Gearry, R. B., Barclay, M. L., & Philpott, M. (2008). Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population. Digestive & Liver Disease, 40(9), 723-730. doi: 10.1016/j.dld.2008.02.011

Gardiner, S. J., Gearry, R. B., Burt, M. J., Ding, S. L., & Barclay, M. L. (2008). Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. European Journal of Gastroenterology & Hepatology, 20(12), 1238-1242. doi: 10.1097/MEG.0b013e3282ffda37

Tarrant, K. M., Barclay, M. L., Frampton, C. M. A., & Gearry, R. B. (2008). Perianal disease predicts changes in Crohn's disease phenotype: Results of a population-based study of inflammatory bowel disease phenotype. American Journal of Gastroenterology, 103(12), 3082-3093.

Roberts, R. L., Gearry, R. B., Bland, M. V., Sies, C. W., George, P. M., Burt, M., … Barclay, M. L., & Kennedy, M. A. (2008). Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenetics & Genomics, 18(5), 434-438.

Gardiner, S. J., Gearry, R. B., Begg, E. J., Zhang, M., & Barclay, M. L. (2008). Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clinical Gastroenterology & Hepatology, 6(6), 654-660. doi: 10.1016/j.cgh.2008.02.032

Bentley, R. W., Keenan, J. I., Gearry, R. B., Kennedy, M. A., Barclay, M. L., & Roberts, R. L. (2008). Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. American Journal of Gastroenterology, 103(5), 1168-1172. doi: 10.1111/j.1572-0241.2007.01742.x

Roberts, R. L., Hollis-Moffatt, J. E., Gearry, R. B., Kennedy, M. A., Barclay, M. L., & Merriman, T. R. (2008). Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes & Immunity, 9(6), 561-565. doi: 10.1038/gene.2008.49

Roberts, R. L., Gearry, R. B., Kennedy, M. A., & Barclay, M. L. (2008). Beyond TPMT: Genetic influences on thiopurine drug responses in inflammatory bowel disease. Personalized Medicine, 5(3), 233-248. doi: 10.2217/17410541.5.3.233

Browning, B. L., Annese, V., Barclay, M. L., Bingham, S. A., Brand, S., Büning, C., … Gearry, R. B., … Witt, H. (2008). Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. Journal of Medical Genetics, 45(1), 36-42. doi: 10.1136/jmg.2007.050773

Conference Contribution - Published proceedings: Abstract

Gearry, R. B., Roberts, R. L., Kennedy, M. A., Zhang, M., & Barclay, M. L. (2008). Thiopurine metabolites, intermediate steps on the way to complete thiopurine pharmacogenetics. Proceedings of the 4th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.chmeds.ac.nz/research/carneycentre/symposium.htm

Roberts, R. L., Gearry, R. B., Zhang, M., Begg, E. J., & Barclay, M. L. (2008). Optimisation of methotrexate in inflammatory bowel disease patients. Proceedings of the 4th Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.chmeds.ac.nz/research/carneycentre/symposium.htm

Frizelle, F., Gearry, R., & Barclay, M. (2008). Surgery for perianal disease in a population-based Crohn's disease cohort. Diseases of the Colon & Rectum. 51(5), (pp. 669). doi: 10.1007/s10350-008-9314-4

Barclay, M. L., Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., … Stedman, C. A. M. (2008). Allopurinol may improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology and Hepatology. 23(Suppl. 4), (pp. A194). [Abstract]

Gearry, R. B., Tarrant, K. M., Shirley, P. M., Frampton, C. M., & Barclay, M. L. (2008). Perianal disease predicts changes in Crohn's disease phenotype: Results of a population-based study of inflammatory bowel disease phenotype. Journal of Gastroenterology & Hepatology, 23(Suppl. 4), (pp. A178). doi: 10.1111/j.1440-1746.2008.05610.x

Chalmers-Watson, T. A., Tarrant, K. M., Barclay, M., Shirley, P. M., Frampton, C. M. A., & Gearry, R. B. (2008). Prevalence of extra-intestinal manifestations of inflammatory bowel disease in a population-based cohort. Journal of Gastroenterology & Hepatology, 23(Suppl. 4), (pp. A221). doi: 10.1111/j.1440-1746.2008.05611.x

Frizelle, F., Barclay, M., & Gearry, R. (2008). Characteristics of resectional surgery in a population-based inflammatory bowel disease cohort. Diseases of the Colon & Rectum. 51(5), (pp. 671). doi: 10.1007/s10350-008-9314-4

Barclay, M. L., Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., … Stedman, C. A. M. (2008). Allopurinol may improve response to azathioprine and 6-mercaptopurine by correcting an unfavourable metabolite ratio. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf

Dalrymple, J., Stamp, L. K., O'Donnell, J., Chapman, P., Zhang, M., & Barclay, M. (2008). Pharmacokinetics of oral MTX in RA patients. Arthritis & Rheumatism, 58(Suppl.9), (pp. S311). [Abstract]

Stamp, L. K., O'Donnell, J., Chapman, P., Zhang, M., Frampton, C., & Barclay, M. (2008). Methotrexate polyglutamates and disease activity in rheumatoid arthritis. Arthritis & Rheumatism, 58(Suppl. 9), (pp. S544). [Abstract]

Conference Contribution - Poster Presentation (not in published proceedings)

Chalmers-Watson, T. A., Tarrant, K. M., Frampton, C. M., Barclay, M. L., & Gearry, R. B. (2008, November). Extra-intestinal manifestations of Inflammatory Bowel Disease in a population_based cohort. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Rotorua, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Roberts, R., Hollis-Moffatt, J. E., Gearry, R. B., Barclay, M. L., & Merriman, T. R. (2008, November). Genetics of inflammatory bowel disease and intestinal permeability. Verbal presentation at the Medical Sciences Congress, Queenstown, New Zealand.

Bentley, R., Glubb, D. M., Keenan, J. I., Gearry, R. B., Barclay, M. L., & Roberts, R. L. (2008, November). Mycobacterium Avium subsp. Paratuberculosis associated with Crohn's disease in New Zealand. Verbal presentation at the Medical Sciences Congress, Queenstown, New Zealand.

Tarrant, K. M., Frampton, C. M., Barclay, M. L., & Gearry, R. B. (2008, November). Perianal disease predicts changes in Crohn's disease phenotype: Results of a population-based study of Inflammatory Bowel Disease phenotype. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Rotorua, New Zealand.

Gearry, R. B., Roberts, R. L., Kennedy, M. A., Zhang, M., & Barclay, M. L. (2008, October). Thiopurine metabolites, intermediate steps on the way to complete thiopurine pharmacogenetics. Verbal presentation at the 4th Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Roberts, R. L., Gearry, R. B., Zhang, M., Begg, E. J., & Barclay, M. L. (2008, October). Optimisation of methotrexate in inflammatory bowel disease patients. Verbal presentation at the 4th Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

2007

Journal - Research Article

Browning, B. L., Huebner, C., Petermann, I., Demmers, P., McCulloch, A., Gearry, R. B., Barclay, M. L., … Ferguson, L. R. (2007). Association of DLG5 variants with inflammatory bowel disease in the New Zealand caucasian population and meta-analysis of the DLG5 R30Q variant. Inflammatory Bowel Diseases, 13(9), 1069-1076.

Browning, B. L., Huebner, C., Petermann, I., Gearry, R. B., Barclay, M. L., Shelling, A. N., & Ferguson, L. R. (2007). Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. American Journal of Gastroenterology, 102, 2504-2512.

Brooks, A. J., Begg, E. J., Zhang, M., Frampton, C. M., & Barclay, M. L. (2007). Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Therapeutic Drug Monitoring, 29(5), 619-625.

Roberts, R. L., Gearry, R. B., Hollis-Moffatt, J. E., Miller, A. L., Reid, J., Abkevich, V., … Merriman, T. R., Barclay, M. L., & Kennedy, M. A. (2007). IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. American Journal of Gastroenterology, 102, 2754-2761.

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2007). IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics Journal, 7(5), 312-317.

Gearry, R. B., Roberts, R. L., Burt, M. J., Frampton, C. M. A., Chapman, B. A., Collett, J. A., Shirley, P., Allington, M. D. E., Kennedy, M. A., & Barclay, M. L. (2007). Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflammatory Bowel Diseases, 13(10), 1220-1227.

Journal - Research Other

Gardiner, S. J., Begg, E. J., Sau, A., Marinaki, A., Gearry, R. B., & Barclay, M. L. (2007). Thiopurine treatment in inflammatory bowel disease [Letter to the editor]. Clinical Pharmacokinetics, 46(9), 803-804.

Gardiner, S. J., Gearry, R. B., Roberts, R. L., Zhang, M., Barclay, M. L., & Begg, E. J. (2007). Breast-feeding during maternal use of azathioprine [Comment]. Annals of Pharmacotherapy, 41(4), 719-720.

Conference Contribution - Published proceedings: Abstract

Barclay, M., Roberts, R., Gearry, R., & Kennedy, M. (2007). Inflammatory bowel disease pharmacogenetics. Proceedings of the 3rd Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.chmeds.ac.nz/research/carneycentre/symposium.htm

Gardiner, S. J., Gearry, R. B., Begg, E. J., & Barclay, M. L. (2007). Thiopurine methyltransferase (TPMT) and thiopurine dose in inflammatory bowel disease (IBD). Proceedings of the 3rd Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.chmeds.ac.nz/research/carneycentre/symposium.htm

Roberts, R. L., Gearry, R. B., Bland, M. V., Sies, C., George, P. M., Burt, M., Kennedy, M. A., & Barclay, M. L. (2007). Trinucleotide repeat variants in inflammatory bowel disease patients exhibiting ultra-high thiopurine S-methyltransferase activity. Proceedings of the 3rd Annual Carney Pharmacogenomics Symposium. Retrieved from http://www.chmeds.ac.nz/research/carneycentre/symposium.htm

Ngu, J. H., Bechly, K., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2007). Prevalence of autoimmune hepatitis in Canterbury, New Zealand: A retrospective population based survey. New Zealand Medical Journal, 120(1266). Retrieved from http://journal.nzma.org.nz/journal/120-1266/2848/content.pdf

Roberts, R. L., Gearry, R. B., Hollis-Moffatt, J. E., Miller, A. L., Reid, J., Abkevich, V., … Merriman, T. R., Barclay, M. L., & Kennedy, M. A. (2007). IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. New Zealand Medical Journal, 120(1266). Retrieved from http://journal.nzma.org.nz/journal/120-1266/2848/content.pdf

Barclay, M. L., Brooks, A. J., Begg, E. J., Zhang, M., & Frampton, C. M. (2007). Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Journal of Gastroenterology and Hepatology. 22(Suppl. 3), (pp. A315). [Abstract]

Chang, H., Gearry, R. B., Reilly, M. J., Barclay, M. L., & Frizelle, F. A. (2007). Characteristics of resectional surgery in a population-based inflammatory bowel disease cohort. Gut. 56(Suppl. III), (pp. A81). [Abstract]

Reilly, M. J., Chang, Y., Gearry, R. B., Barclay, M. L., & Frizelle, F. A. (2007). Surgery for perianal disease in a population-based Crohn's disease cohort. Gut. 56(Suppl. III), (pp. A163). [Abstract]

Gearry, R. B., Frampton, C. M., Collett, J. A., Chapman, B. A., Burt, M. J., Shirley, P. M., & Barclay, M. L. (2007). Inflammatory bowel disease (IBD) related morbidity in a population-based cohort. Gut. 56(Suppl. III), (pp. A127). [Abstract]

Bentley, R. W., Gearry, R. B., Keenan, J. I., Aitken, J. M., Kennedy, M. A., Barclay, M. L., & Roberts, R. L. (2007). Relative incidence of Mycobacterium avium subsp. paratuberculosis in a population-based cohort of Crohn's disease patients. Gut. 56(Suppl. III), (pp. A127). [Abstract]

Barclay, M. L., Shirley, P. M., Ailabouni, R., & Gearry, R. B. (2007). High immunomodulator use in inflammatory bowel disease in New Zealand. Gut. 56(Suppl. III), (pp. A151). [Abstract]

Barclay, M. L., Ailabouni, R., & Gearry, R. B. (2007). Complementary and alternative medicine use in IBD is determined by age, sex and socioeconomic status and is no different than in controls without IBD. Gut. 56(Suppl. III), (pp. A151). [Abstract]

Roberts, R. L., Gearry, R. B., Hollis-Moffatt, J. E., Miller, A. L., Reid, J., Abkevich, V., … Merriman, T. R., Barclay, M. L., & Kennedy, M. A. (2007). IL23R R381Q & ATG16L1 T300A are associated with Crohn's disease in a population-based New Zealand Caucasian cohort. Gut. 56(Suppl. III), (pp. A19). [Abstract]

Brown, R. E., Hoar, J. A., Barclay, M. L., & Gearry, R. B. (2007). A cross-sectional study of nutritional markers in a population-based Crohn's disease (CD) cohort. Journal of Gastroenterology & Hepatology, 22(Suppl. 3), (pp. A401). doi: 10.1111/j.1440-1746.2007.05163.x

Barclay, M. L., Ailabouni, R., Shirley, P. M., & Gearry, R. B. (2007). Pattern of medication use in a population-based inflammatory bowel disease cohort in New Zealand. Journal of Gastroenterology & Hepatology, 22(Suppl. 3), (pp. A288). doi: 10.1111/j.1440-1746.2007.05159.x

Stamp, L., Barclay, M., Zhang, M., James, J., Frampton, C., O'Donnell, J., & Chapman, P. (2007). Red cell folate may be an important determinant of response to methotrexate in rheumatoid arthritis. Internal Medicine Journal, 37(Suppl. 2), (pp. A54). doi: 10.1111/j.1445-5994.2007.01428.x

Hoar, J. A., Brown, R. E., Gearry, R. B., & Barclay, M. L. (2007). Audit of blood test monitoring for patients on azathioprine or 6-MP for inflammatory bowel disease. Journal of Gastroenterology & Hepatology, 22(Suppl. 3), (pp. A278). doi: 10.1111/j.1440-1746.2007.05159.x

Reilly, M. J., Chang, Y.-H., Gearry, R. B., Barclay, M. L., & Frizelle, F. A. (2007). Surgery for perianal disease in a population-based Crohn's disease cohort. Journal of Gastroenterology & Hepatology, 22(Suppl. 3), (pp. A318). doi: 10.1111/j.1440-1746.2007.05172.x

Chang, Y.-H., Gearry, R. B., Reilly, M. J., Barclay, M. L., & Frizelle, F. A. (2007). Resectional surgery characteristics in a population-based inflammatory bowel disease (IBD) cohort. Journal of Gastroenterology & Hepatology, 22(Suppl. 3), (pp. A317). doi: 10.1111/j.1440-1746.2007.05172.x

Bentley, R. W., Roberts, R. L., Gearry, R. B., Merriman, T. R., Kennedy, M. A., & Barclay, M. L. (2007). The GLI1 gene as a risk factor for ulcerative colitis. Journal of Gastroenterology & Hepatology, 22(Suppl. 3), (pp. A321). doi: 10.1111/j.1440-1746.2007.05172.x

Bentley, R. W., Gearry, R. B., Keenan, J. I., Aitken, J. M., Kennedy, M. A., Barclay, M. L., & Roberts, R. L. (2007). Relative incidence of Mycobacterium avium subsp. paratuberculosis in a population-based cohort of Crohn's disease patients. Journal of Gastroenterology and Hepatology. 22(Suppl. 3), (pp. A317). [Abstract]

Roberts, R. L., Gearry, R. B., Hollis-Moffatt, J. E., Miller, A. L., Reid, J., Abkevich, V., … Merriman, T. R., Barclay, M. L., & Kennedy, M. A. (2007). IL23R R381Q & ATG16L1 T300A are associated with Crohn's disease in a population-based Caucasian cohort. Journal of Gastroenterology & Hepatology, 22(Suppl. 3), (pp. A305). doi: 10.1111/j.1440-1746.2007.05172.x

Gearry, R., Nolan, R., Roberts, R., Barclay, M., Kennedy, M. A., Patterson, A., … Nolan, D. (2007). HLA, TPMT and ITPA genotypes and susceptibility to azathioprine hypersensitivity reactions (HSR) in inflammatory bowel disease (IBD) patients. Journal of Gastroenterology & Hepatology, 22(Suppl. 3), (pp. A304). doi: 10.1111/j.1440-1746.2007.05172.x

Bentley, R. W., Roberts, R. L., Gearry, R. B., Merriman, T. R., Kennedy, M. A., & Barclay, M. L. (2007). The GLI1 gene as a risk factor for ulcerative colitis GLI1. Proceedings of the American Society of Human Genetics 57th Annual Meeting. Retrieved from http://www.ashg.org/genetics/ashg/annmeet/2007/call/postersessionlisting.shtml

Conference Contribution - Poster Presentation (not in published proceedings)

Hoar, J. A., Brown, R. E., Gearry, R. B., & Barclay, M. L. (2007, November). Audit of blood test monitoring for patients on azathioprine or 6-mp for inflammatory bowel disease. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.

Brown, R. E., Hoar, J. A., Barclay, M. L., & Gearry, R. B. (2007, November). A cross-sectional study of nutritional markers in a population-based Crohn's disease (CD) cohort. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.

Gearry, R. B., Montgomery, S. M., Frampton, C. M., & Barclay, M. L. (2007, November). A systematic review of case-control studies assessing environmental factors associated with inflammatory bowel disease (IBD). Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.

Chang, Y.-H., Gearry, R. B., Reilly, M. J., Barclay, M. L., & Frizelle, F. A. (2007, November). Resection surgery characteristics in a population-based inflammatory bowel disease (IBD) cohort. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.

Reilly, M. J., Chang, Y.-H., Gearry, R. B., Barclay, M. L., & Frizelle, F. A. (2007, November). Surgery for perianal disease in a population-based Crohn's disease cohort. Poster session presented at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Bentley, R. W., Roberts, R. L., Gearry, R. B., Keenan, J. I., Kennedy, M. A., & Barclay, M. L. (2007, November). Relative incidence of Mycobacterium avium subsp. paratuberculosis in a New Zealand population-based cohort of patients with Crohn's disease. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Frampton, C., Barclay, M. L., Kennedy, M., & Roberts, R. L. (2007, August-September). HLA-G 14BP polymorphism is not associated with response to methotrexate in rheumatoid arthritis. Verbal presentation at the New Zealand Rheumatology Association Conference, Dunedin, New Zealand.

Dalrymple, J., Barclay, M., Chapman, P., O'Donnell, J., Zhang, M., & Stamp, L. (2007, August-September). The elimination of red blood cell methotrexate polyglutamates in patients with rheumatoid arthritis. Verbal presentation at the New Zealand Rheumatology Association Conference, Dunedin, New Zealand.

Dalrymple, J. M., Stamp, L. K., Zhang, M., Chapman, P. T., O'Donnell, J. L., & Barclay, M. L. (2007, August). The elimination of red blood cell methotrexate polyglutamates in patients with rheumatoid arthritis. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (NZ) Annual Scientific Meeting, Auckland, New Zealand.

Barclay, M. L., Roberts, R. L., Gearry, R. B., Zhang, M., & Kennedy, M. A. (2007, August). Novel gene mutations for enzymes in the thiopurine metabolic pathway in patients with inflammatory bowel disease and severe azathioprine resistance. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (NZ) Annual Scientific Meeting, Auckland, New Zealand.

Zhang, M., Moore, G. A., Stamp, L., Barclay, M. L., & Begg, E. J. (2007, August). Rapid and simple HPLC assay for the determination of allopurinol and oxypurinol in human plasma. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (NZ) Annual Scientific Meeting, Auckland, New Zealand.

Roberts, R. L., Gearry, R. B., Bland, M. V., Sies, C. W., George, P. M., Burt, M., Kennedy, M. A., & Barclay, M. L. (2007, October). Promoter insertion in an inflammatory bowel disease patient exhibiting ultra-high thiopurine S-methyltransferase activity. Verbal presentation at the Joint Cold Spring Harbor Laboratory/Wellcome Trust Conference, Cold Spring Harbor, New York.

Roberts, R. L., Gearry, R. B., Hollis-Moffatt, J. E., Miller, A. L., Reid, J., Abkevich, V., … Merriman, T. R., Barclay, M. L., & Kennedy, M. A. (2007, November). IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.

Gardiner, S. J., Gearry, R. B., Begg, E. J., & Barclay, M. L. (2007, September). Thiopurine methyltransferase (TPMT) and thiopurine dose in inflammatory bowel disease (IBD). Verbal presentation at the 3rd Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Roberts, R. L., Gearry, R. B., Bland, M. V., Sies, C. W., George, P. M., Burt, M., Kennedy, M. A., & Barclay, M. L. (2007, September). Trinucleotide repeat variants in inflammatory bowel disease patients exhibiting ultra-high thiopurine S-methyltransferase activity. Verbal presentation at the 3rd Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Barclay, M., Roberts, R., Gearry, R., & Kennedy, M. (2007, September). Inflammatory bowel disease pharmacogenetics. Verbal presentation at the 3rd Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Ngu, J. H., Bechly, K., Gearry, R. B., Chapman, B. A., Burt, M. J., Barclay, M. L., & Stedman, C. A. M. (2007, November). Prevalence of autoimmune hepatitis in Canterbury, New Zealand: A retrospective population based survey. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting combined with the RACP and IMSANZ, Christchurch, New Zealand.

Intellectual Property

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2007). Method of identifying individuals at risk of thiopurine drug resistance and intolerance. International (PCT) Patent Application (PCT/NZ2007/000329).

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2007). Method of identifying individuals at risk of thiopurine drug resistance and intolerance. United States Patent Application (60/935367).

2006

Journal - Research Article

Frizelle, F., & Barclay, M. (2006). Constipation in adults. Clinical Evidence, 15. Retrieved from http://clinicalevidence.bmj.com/ceweb/conditions/dsd/0413/0413.jsp

Cameron, R., Barclay, M., & Dobbs, B. (2006). Ambulatory oesophageal manometry and pH monitoring for investigation of chest pain: A New Zealand experience. New Zealand Medical Journal, 119(1230). Retrieved from http://journal.nzma.org.nz/journal/119-1230/1877/content.pdf

Gardiner, S. J., Gearry, R. B., Roberts, R. L., Zhang, M., Barclay, M. L., & Begg, E. J. (2006). Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. British Journal of Clinical Pharmacology, 62(4), 453-456.

Gearry, R. B., Richardson, A., Frampton, C. M., Collett, J. A., Burt, M. J., Chapman, B. A., & Barclay, M. L. (2006). High incidence of Crohn's disease in Canterbury, New Zealand: Results of an epidemiologic study. Inflammatory Bowel Diseases, 12(10), 936-943.

Priest, V. L., Begg, E. J., Gardiner, S. J., Frampton, C. M., Gearry, R. B., Barclay, M. L., Clark, D. W., & Hansen, P. (2006). Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics, 24(8), 767-781.

Gardiner, S. J., Gearry, R. B., Barclay, M. L., & Begg, E. J. (2006). Two cases of thiopurine methyltransferase (TPMT) deficiency: A lucky save and a near miss with azathioprine. British Journal of Clinical Pharmacology, 62(4), 473-476. doi: 10.1111/j.1365-2125.2005.02474.x

Journal - Research Other

Gearry, R. B., Lea, R. A., Roberts, R. L., Chambers, G. K., Barclay, M. L., & Kennedy, M. A. (2006). CARD15 allele frequency differences in New Zealand Maori: Ancestry specific susceptibility to Crohn's disease in New Zealand? [Letter]. Gut, 55, 580. doi: 10.1136/gut.2005.085464

Stamp, L., Roberts, R., Kennedy, M., Barclay, M., O'Donnell, J., & Chapman, P. (2006). The use of low dose methotrexate in rheumatoid arthritis: Are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomedicine & Pharmacotherapy, 60, 678-687.

Conference Contribution - Published proceedings: Abstract

Gearry, R. B., Roberts, R. R., Richardson, A., Frampton, C. M. A., Kennedy, M. A., & Barclay, M. L. (2006). The prevalence and genetic determinants of inflammatory bowel disease (IBD) in Canterbury. New Zealand Medical Journal, 119(1231). Retrieved from http://journal.nzma.org.nz/journal/119-1231/1922/content.pdf

Kennedy, M. A., Roberts, R. R., Gearry, R. B., Barclay, M. L., Taylor, D. R., Begg, E. J., Clark, D. W. J., & Joyce, P. R. (2006). Pharmacogenetics and genomics ″Down Under″: Focus on asthma, inflammatory bowel disease, and major depression. Proceedings of the Pharmacogenomics Meeting. (pp. 11). NY: Cold Spring Harbor Laboratory. [Abstract]

Gardiner, S. J., Gearry, R. B., Begg, E. J., & Barclay, M. L. (2006). Thiopurine methyltransferase (TPMT) and thiopurine dose in inflammatory bowel disease (IBD). Proceedings of the Australian Health and Medical Research Congress. (pp. 247). Sydney, Australia: Australian Health and Medical Research Congress. [Abstract]

Gearry, R. B., Richardson, A., Frampton, C. M., Chapman, B. A., Burt, M. J., Collett, J. A., & Barclay, M. L. (2006). High rate of Crohn's disease in Canterbury, New Zealand: Results of a population-based study. Gastroenterology. 130(4, Suppl. 2), (pp. A-622). [Abstract]

Gearry, R. B., Frampton, C. M., Collett, J. A., Chapman, B. A., Burt, M. J., Shirley, P., & Barclay, M. L. (2006). Inflammatory bowel disease (IBD) related morbidity in a population-based cohort. Journal of Gastroenterology & Hepatology, 21(Suppl. 4), (pp. A274). doi: 10.1111/j.1440-1746.2006.04687.x

Gearry, R. B., Roberts, R. L., Frampton, C. M., Burt, M. J., Collett, J. A., Chapman, B. A., Allington, M. D., Kennedy, M. A., & Barclay, M. L. (2006). From Vienna to Montreal: The impact of changes in IBD classification on CARD15 genotype-phenotype relationships in a population-based cohort. Journal of Gastroenterology & Hepatology, 21(Suppl. 4), (pp. A271). doi: 10.1111/j.1440-1746.2006.04687.x

Gearry, R. B., Richardson, A., Frampton, C. M., Collett, J. A., Dodgshun, A., Chapman, B. A., Burt, M. J., & Barclay, M. L. (2006). Environmental factors associated with ulcerative colitis: A population-based case-control study. Journal of Gastroenterology & Hepatology, 21(Suppl. 4), (pp. A271). doi: 10.1111/j.1440-1746.2006.04687.x

Gearry, R. B., Richardson, A., Frampton, C. M., Collett, J. A., Dodgshun, A., Chapman, B. A., Burt, M. J., & Barclay, M. L. (2006). Environmental factors associated with Crohn's disease: A population-based case-control study. Journal of Gastroenterology & Hepatology, 21(Suppl. 4), (pp. A270). doi: 10.1111/j.1440-1746.2006.04687.x

Gearry, R. B., Montgomery, S. M., Frampton, C. M., & Barclay, M. L. (2006). A systematic review of case-control studies assessing environmental factors associated with inflammatory bowel disease (IBD). Journal of Gastroenterology & Hepatology, 21(Suppl. 4), (pp. A261). doi: 10.1111/j.1440-1746.2006.04687.x

Barclay, M. L., Gardiner, S. J., Gearry, R. B., Roberts, R. L., Zhang, M., & Begg, E. J. (2006). Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Journal of Gastroenterology & Hepatology, 21(Suppl. 4), (pp. A252). doi: 10.1111/j.1440-1746.2006.04686.x

Gearry, R. B., Richardson, A., Frampton, C. M., Collett, J. A., Dodgshun, A., Chapman, B. A., Burt, M. J., & Barclay, M. L. (2006). Environmental factors associated with Crohn's disease: A population-based case-control study. Gastroenterology. 130(4, Suppl. 2), (pp. A-621). [Abstract]

Gearry, R. B., Roberts, R. L., Frampton, C. M., Burt, M. J., Collett, J. A., Chapman, B. A., Allington, M. D., Kennedy, M. A., & Barclay, M. L. (2006). From Vienna to Montreal: The impact of changes in IBD classification on CARD15 genotype-phenotype relationships in a population-based cohort. Gastroenterology. 130(4, Suppl. 2), (pp. A-586). [Abstract]

Gearry, R. B., Richardson, A., Frampton, C. M., Collett, J. A., Dodgshun, A., Chapman, B. A., Burt, M. J., & Barclay, M. L. (2006). Environmental factors associated with ulcerative colitis: A large population-based case-control study. Gastroenterology. 130(4, Suppl. 2), (pp. A-137). [Abstract]

Barclay, M. L., Ailabouni, R., Gearry, R. B., & Frampton, C. (2006). Complementary and alternative medicine use in IBD is determined by age, sex and socioeconomic status and is no different than in controls without IBD. Journal of Gastroenterology & Hepatology, 21(Suppl. 4), (pp. A251). doi: 10.1111/j.1440-1746.2006.04686.x

Conference Contribution - Poster Presentation (not in published proceedings)

Roberts, R. L., Gearry, R. B., Kennedy, M. A., & Barclay, M. L. (2006, November-December). Mutations in the guanosine 5'-monophosphate synthetase (GMPS) gene are associated with thiopurine resistance. Poster session presented at the Medical Sciences Congress, Rotorua, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Barclay, M. (2006, June). Pharmacogenetics of inflammatory bowel disease: View from the clinic. Verbal presentation at the 2nd Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.

Gearry, R., Frampton, C., Collett, J., Chapman, B., Burt, M., Shirley, P., & Barclay, M. (2006, November). Inflammatory bowel disease (IBD) related morbidity in a population-based cohort. Verbal presentation at the New Zealand Society of Gastroenterology NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Blenheim, New Zealand.

Barclay, M. L., Ailabouni, R., Gearry, R. B., & Frampton, C. (2006, August-September). Complementary and alternative medicine use in inflammatory bowel disease (IBD) is determined by age, sex and socioeconomic status and is no different than in controls without IBD. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (New Zealand) Annual Scientific Meeting, Auckland, New Zealand.

Brooks, A. J., Barclay, M. L., Begg, E. J., Zhang, M., & Frampton, C. M. A. (2006, November). Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Verbal presentation at the New Zealand Society of Gastroenterology NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Blenheim, New Zealand.

Stamp, L., Dalrymple, J., Barclay, M., Zhang, M., James, J., Frampton, C., Chapman, P., & O'Donnell, J. (2006, August-September). Methotrexate management in rheumatoid arthritis: Is there a role for methotrexate polyglutamate measurement? Verbal presentation at the New Zealand Rheumatology Association Annual Scientific Meeting, Queenstown, New Zealand.

Brooks, A. J., Begg, E. J., Barclay, M. L., & Zhang, M. (2006, August-September). Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (New Zealand) Annual Scientific Meeting, Auckland, New Zealand.

Gardiner, S. J., Gearry, R. B., Begg, E. J., & Barclay, M. L. (2006, August-September). Thiopurine methyltransferase (TPMT) and thiopurine dose in inflammatory bowel disease (IBD). Verbal presentation at the Australasian Society of Clinical Experimental Pharmacologists & Toxicologists (New Zealand) Annual Scientific Meeting, Auckland, New Zealand.

Dalrymple, J., Barclay, M., Zhang, M., Chapman, P., O'Donnell, J., Frampton, C., & Stamp, L. (2006, August-September). The pharmacokinetics of accumulation of methotrexate polyglutamates in patients with rheumatoid arthritis. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (New Zealand) Annual Scientific Meeting, Auckland, New Zealand.

Dalrymple, J., Barclay, M., Zhang, M., Chapman, P., O'Donnell, J., Frampton, C., & Stamp, L. (2006, November). The pharmacokinetics of accumulation of methotrexate polyglutamates in patients with rheumatoid arthritis. Verbal presentation at the Society of Hospital Pharmacists of Australia 5th Biennial Clinical Conference, Melbourne, Australia.

Roberts, R., Gardiner, S. J., Gearry, R. B., Bockett, N., & Barclay, M. L. (2006, August-September). Do mutations within inosine triphosphatase predict early intolerance to azathioprine? Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (New Zealand) Annual Scientific Meeting, Auckland, New Zealand.

2005

Journal - Research Article

Frizelle, F., & Barclay, M. (2005). Constipation in adults. Clinical Evidence, 14, 557-566.

Sies, C., Florkowski, C., George, P., Gearry, R., Barclay, M., Harraway, J., … Walmsley, T. (2005). Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. New Zealand Medical Journal, 118(1210). Retrieved from http://journal.nzma.org.nz/journal/118-1210/1324/content.pdf

Gearry, R. B., & Barclay, M. L. (2005). Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology & Hepatology, 20(8), 1149-1157.

Huckabee, M. L., Butler, S. G., Barclay, M., & Jit, S. (2005). Submental surface electromyographic measurement and pharyngeal pressures during normal and effortful swallowing. Archives of Physical Medicine & Rehabilitation, 86(11), 2144-2149.

Gearry, R. B., Barclay, M. L., Roberts, R. L., Harraway, J., Zhang, M., Pike, L. S., George, P. M., & Florkowski, C. M. (2005). Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: Early experience of use in clinical practice. Internal Medicine Journal, 35, 580-585.

Gearry, R., Barclay, M., Florkowski, C., George, P., & Walmsley, T. (2005). Faecal calprotectin: The case for a novel non-invasive way of assessing intestinal inflammation [Viewpoint]. New Zealand Medical Journal, 118(1214). Retrieved from http://journal.nzma.org.nz/journal/118-1214/1444/content.pdf

Journal - Research Other

Gearry, R. B., Aitken, J. M., Roberts, R. L., Ismail, S. L., Keenan, J., & Barclay, M. L. (2005). Gastrointestinal: Mycobacterium avium paratuberculosis and Crohn's disease. Journal of Gastroenterology & Hepatology, 20(12), 1943. doi: 10.1111/j.1440-1746.2005.04187.x

Conference Contribution - Published proceedings: Abstract

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2005). Interim CARD15 genotype results from a population-based study of Inflammatory Bowel Disease. European Journal of Human Genetics, 13(Suppl. 1), (pp. 304). [Abstract]

Zhang, M., Moore, G. A., Barclay, M. L., & Stamp, L. (2005). HPLC assay for erythrocyte methotrexate polyglutamates. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting. Wellington, New Zealand: ASCEPT. [Abstract]

Conference Contribution - Poster Presentation (not in published proceedings)

Barclay, M. L., Gearry, R. B., Frampton, C. M. A., Richardson, A. K., & Dodgshun, A. (2005, September). Increasing duration of breastfeeding is associated with a decreasing risk of Crohn's disease in later life. Poster session presented at the World Congress of Gastroenterology, Montréal, Canada.

Barclay, M. L., Roberts, R. L., Gearry, R. B., & Kennedy, M. A. (2005, September). Interim CARD15 genotype results from a population-based study of inflammatory bowel disease in New Zealand. Poster session presented at the World Congress of Gastroenterology, Montréal, Canada.

Barclay, M. L., Begg, E. J., Gefken, T., & Doogue, M. P. (2005, December). Interactive computer graphics for enhancing learning of clinical pharmacology. Poster session presented at the Joint Meeting of ASCEPT and APSA, Melbourne, Australia.

Conference Contribution - Verbal presentation and other Conference outputs

Zhang, M., Moore, G. A., Barclay, M. L., & Stamp, L. (2005, August). HPLC assay for erythrocyte methotrexate polyglutamates. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting, Wellington, New Zealand.

Cromie, A. J., Doogue, M. P., Vella-Brincat, J., & Barclay, M. L. (2005, August). Therapeutic drug monitoring of tricyclic antidepressants: What is happening in Christchurch? Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting, Wellington, New Zealand.

Barclay, M., Gearry, R., Frampton, C., Richardson, A., & Dodgshun, A. (2005, November). Increasing duration of breastfeeding is associated with a decreasing risk of Crohn's disease in later life. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Hamilton, New Zealand.

Gearry, R., Roberts, R., Richardson, A., Frampton, C., Kennedy, M., & Barclay, M. (2005, November). The epidemiology and genetic determinants of inflammatory bowel disease (IBD) in Canterbury. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Hamilton, New Zealand.

Priest, V. L., Begg, E. J., Gardiner, S. J., Frampton, C. M. A., Gearry, R. B., Barclay, M. L., & Clark, D. W. J. (2005, August). Cost-efficacy of TPMT testing prior to azathioprine therapy. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting, Wellington, New Zealand.

Gardiner, S. J., Begg, E. J., Gearry, R. B., & Barclay, M. L. (2005, August). Tacrolimus and azathioprine in breastfeeding: Are they safe? Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting, Wellington, New Zealand.

Software

Barclay, M., Begg, E., Doogue, M., & Gefken, T. (2005). Interactive Clinical Pharmacology (Version http://www.icp.org.nz/about.htm) [Computer Software]. Dunedin, New Zealand: Department of Clinical Pharmacology, University of Otago. Retrieved from http://www.icp.org.nz/about.htm

2004

Edited Book - Other

Begg, E., Barclay, M., Vella-Brincat, J., Gardiner, S. J., Doogue, M., McDermott, L., … Chambers, S., & Murdoch, D. (Eds.). (2004). Preferred Medicines List (8th ed.). Christchurch: The Caxton Press, 172p.

Journal - Research Article

Frizelle, F. A., & Barclay, M. (2004). Constipation in adults. Clinical Evidence, 12, 610-622.

Gearry, R. B., Roberts, R. L., Barclay, M. L., & Kennedy, M. A. (2004). Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics, 14(11), 779-781.

Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., & Chapman, B. A. (2004). Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiology & Drug Safety, 13(8), 563-567.

Roberts, R. L., Barclay, M. L., Gearry, R. B., & Kennedy, M. A. (2004). A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clinica Chimica Acta, 341(1-2), 49-53.

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2004). Rapid detection of common CARD15 variants in patients with inflammatory bowel disease. Molecular Diagnosis, 8(2), 101-105. doi: 10.1007/BF03260052

Frizelle, F. A., Gearry, R. B., Johnston, M., Barclay, M. L., Dobbs, B. R., Wise, C., & Troughton, W. D. (2004). Penile and clitoral stimulation for faecal incontinence: External application of a bipolar electrode for patients with faecal incontinence. Colorectal Disease, 6(1), 54-57. doi: 10.1111/j.1463-1318.2004.00543.x

Leaper, M., Johnston, M. J., Barclay, M., Dobbs, B. R., & Frizelle, F. A. (2004). Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Endoscopy, 36(6), 499-503.

Gearry, R. B., Wakeman, C. J., Barclay, M. L., Chapman, B. A., Collett, J. A., Burt, M. J., & Frizelle, F. A. (2004). Surveillance for dysplasia in patients with inflammatory bowel disease: A national survey of colonoscopic practice in New Zealand. Diseases of the Colon & Rectum, 47(3), 314-322.

Journal - Research Other

Frizelle, F., & Barclay, M. (2004). Who misses the cancers at colonoscopy? Reply to Fracasso et al [Letter to the editor]. Endoscopy, 36, 1126-1127.

Conference Contribution - Published proceedings: Abstract

Gearry, R., Barclay, M., Burt, M., Chapman, B., Collett, J., & George, P. (2004). Comparison of faecal calprotectin and clinical disease indices for assessing inflammation in Crohn's disease. New Zealand Medical Journal, 117(1195). Retrieved from http://journal.nzma.org.nz/journal/117-1195/916/content.pdf

Barclay, M. L., Patton, N., Kirkpatrick, C. M. J., Moore, G. A., & Doogue, M. P. (2004). Population pharmacokinetic analysis of high-dose oral busulphan for bone marrow transplantation in adults and children. Clinical & Experimental Pharmacology & Physiology, 31(Suppl. 1), (pp. A174). doi: 10.1111/j.1440-1681.2004.cep_4027.pdf.x

Zhang, M., Moore, G. A., Lever, M., Barclay, M. L., & Begg, E. J. (2004). Therapeutic drug monitoring of fluoxetine and norfluoxetine enantiomers. Clinical and Experimental Pharmacology and Physiology. 31(Suppl.), (pp. A56). [Abstract]

2003

Journal - Research Article

Frizelle, F. A., & Barclay, M. L. (2003). Constipation in adults. Clinical Evidence. Retrieved from http://www.clinicalevidence.com/ceweb/conditions/dsd/0413/0413.jsp

Howard, G., Barclay, M., Florkowski, C. M., Moore, G., & Roche, A. L. (2003). Lack of clinically significant interference by spironolactone with the AxSym Digoxin II assay. Therapeutic Drug Monitoring, 25(1), 112-113.

Barclay, M., & Begg, E. (2003). The practice of digoxin therapeutic drug monitoring [Editorial]. New Zealand Medical Journal, 116(1187). Retrieved from http://journal.nzma.org.nz/journal/116-1187/704/content.pdf

Sidwell, A., Barclay, M., Begg, E., & Moore, G. (2003). Digoxin therapeutic drug monitoring: An audit and review. New Zealand Medical Journal, 116(1187). Retrieved from http://journal.nzma.org.nz/journal/116-1187/708/content.pdf

Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., Chapman, B. A., Roberts, R., & Kennedy, M. A. (2003). Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 18, 395-400.

Barclay, M. L., Sawyers, S. M., Begg, E. J., Zhang, M., Roberts, R., Kennedy, M. A., & Elliott, J. M. (2003). Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics, 13(10), 627-632.

Journal - Research Other

Barclay, M. L. (2003). 'Steakhouse syndrome' medical management. New Ethicals Journal, 6(11), 39.

Gearry, R., Barclay, M., Gardiner, S., & Zhang, M. (2003). 6-thioguanine nucleotides and thiopurine methyltransferase activity: Important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP [Letter]. New Zealand Medical Journal, 116(1178). Retrieved from http://journal.nzma.org.nz/journal/116-1178/531/content.pdf

Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Gearry, R. B., Zhang, M., Roberts, R. L., Harraway, J., Pike, L., & Gardiner, S. J. (2003). Early New Zealand experience of monitoring TPMT activity and RBC 6-thioguanine nucleotides in patients on azathioprine or 6-MP. In E. A. Davis & C. G. Sobey (Eds.), Proceedings of the Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists. 10. Victoria, Australia: ASCEPT. [Abstract]

Johnston, M. J., Leaper, M. J., Barclay, M., Dobbs, B. R., & Frizelle, F. A. (2003). Reasons for failure to diagnose colorectal carcinoma at colonoscopy. New Zealand Medical Journal, 116(1168). Retrieved from http://journal.nzma.org.nz/journal/116-1168/308/content.pdf

Frizelle, F. A., Johnston, M. J., Barclay, M. L., Leaper, M. J., & Dobbs, B. R. (2003). Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Diseases of the Colon and Rectum. 46(5), (pp. A51-A52). [Abstract]

Johnston, M., Leaper, M., Barclay, M. L., Dobbs, B. R., & Frizelle, F. A. (2003). Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Colorectal Disease, 5(Suppl. 1), (pp. 46). doi: 10.1046/j.1463-1318.5.s1.7.x

Wakeman, C. J., Gearry, R. B., Frizelle, F. A., Barclay, M. L., Chapman, B. A., Burt, M. J., & Collett, J. (2003). A survey of colonoscopic surveilance for dysplasia in patients with ulcerative colitis. ANZ Journal of Surgery, 73(Suppl.), (pp. A13-A14). doi: 10.1046/j.1445-2197.73.s.3.x

2002

Journal - Research Article

Owen, M., Pike, L. S., George, P. M., Barclay, M. L., & Florkowski, C. M. (2002). Macro-alkaline phosphatase due to IgG κ complex: Demonstration with polyethylene glycol precipitation and immunofixation. Annals of Clinical Biochemistry, 39, 523-525.

Journal - Professional & Other Non-Research Articles

Kirkpatrick, C. M. J., Begg, E. J., Barclay, M. L., & Duffull, S. B. (2002). Aminoglycoside dosage regimens after therapeutic drug monitoring. Clinical Pharmacokinetics, 41(10), 791-792.

Ross, A. G., & Barclay, M. L. (2002). Treatment of irritable bowel syndrome. New Ethicals Journal, 5(4), 37-42. New Zealand: Adis International.

Conference Contribution - Published proceedings: Abstract

Zhang, M., Moore, G. A., & Barclay, M. L. (2002). High-performance liquid chromatographic assay for the determination of 6-thioguanine nucleotides of azathioprine in human red blood cells. Proceedings of the Australasian Society of Clinical and Experiemental Pharmacologists and Toxicologists Annual Meeting. [Abstract]

Barclay, M. L., Gearry, R. B., Burt, M. J., & Collett, J. A. (2002). Azathioprine and 6-mercaptopurine adverse effects and TPMT genotype in patients with inflammatory bowel disease. Proceedings of the Australian Health and Medical Research Congress 2002. (pp. 1345). Australia: National Health & Medical Research Council. [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Barclay, M. L., Gearry, R. B., Burt, M. J., Collett, J. A., Roberts, R. L., & Kennedy, M. A. (2002, August). Azathioprine and 6-mercaptopurine adverse effects and TPMT genotype in patients with inflammatory bowel disease. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Meeting, Christchurch, New Zealand.

Barclay, M. L., Gearry, R. B., Burt, M. J., Collett, J. A., Roberts, R. L., & Kennedy, M. A. (2002, November). Azathioprine and 6-mercaptopurine adverse effects and TPMT genotype in patients with inflammatory bowel disease. Verbal presentation at the Annual Meeting of the New Zealand Society of Gastroenterology, Auckland, New Zealand.

2001

Journal - Research Article

Begg, E. J., Barclay, M. L., & Kirkpatrick, C. M. J. (2001). The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 52(Suppl.), 35S-43S.

Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R., & Barclay, M. L. (2001). Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? British Journal of Clinical Pharmacology, 51, 627-630.

Barclay, M. L., & Begg, E. J. (2001). Aminoglycoside adaptive resistance. Importance for effective dosage regimens. Drugs, 61(6), 713-721.

Von Richter, O., Greiner, B., Fromm, M. F., Fraser, R., Omari, T., Barclay, M. L., … Eichelbaum, M. (2001). Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clinical Pharmacology & Therapeutics, 70, 217-227.

Toumadre, J. P., Barclay, M. L., Fraser, R., Dent, J., Young, R., Berce, M., … Burnett, J. C. (2001). Small intestinal motor patterns in critically ill patients after major abdominal surgery. American Journal of Gastroenterology, 96(8), 2418-2426.

Conference Contribution - Published proceedings: Full paper

Barclay, M. L., Sawyers, S. M., Begg, E. J., Roberts, R. L., Kennedy, M. A., & Elliott, J. M. (2001). Correlation of CYP450 2D6 genotype withperhexiline phenotypic metaboliser status. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 9, (pp. 111). [Full Paper]

2000

Journal - Research Article

Chapman, B. A., Burt, M. J., Frampton, C. M., Collett, J., Yeo, K. H. J., Wilkinson, I. D., … Barclay, M. L., … George, P. M. (2000). The prevalence of viral hepatitis (HAV, HBV & HCV) in the Christchurch community. New Zealand Medical Journal, 113(1118), 394-396.

Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R. L., & Barclay, M. L. (2000). Cytochrome P450 2C9 genotype does not predict incidence of gastric bleeding with non steroidal anti-inflammatory drugs. Proceedings of ASCEPT, 7(April), 57.

Gardiner, S. J., Begg, E. J., Barclay, M. L., & Kirkpatrick, C. M. J. (2000). Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug Reactions & Toxicological Reviews, 19(4), 293-312.

Chapman, B. A., Burt, M. J., Frampton, C. M., Collett, J. A., Yeo, K. H. J., Wilkinson, I. D., … Barclay, M. L., … George, P. M. (2000). The prevalence of viral hepatitis (HAV, HBV and HCV) in the Christchurch community. New Zealand Medical Journal, 113, 394-396.

Journal - Research Other

Stedman, C. A. M., & Barclay, M. L. (2000). Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 14(8), 963-978. doi: 10.1046/j.1365-2036.2000.00788.x

1999

Journal - Research Article

Barclay, M. L., Begg, E. J., Robson, R. A., Peters, W. A., & Ketelbey, J. W. (1999). Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. Alimentary Pharmacology & Therapeutics, 13, 1215-1219.

Menelaou, A., Somogyi, A. A., Barclay, M. L., & Bochner, F. (1999). Simultaneous quantification of amoxycillin and metronidazole in plasma using high-performance liquid chromatography with photodiode array detection. Journal of Chromatography B: Biomedical Sciences & Applications, 731, 261-266.

Barclay, M. L. (1999). Helicobacter pylori update. New Ethicals Journal, 2(3), 35-40.

Begg, E. J., Barclay, M. L., & Kirkpatrick, C. (1999). The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 47, 23-30.

Barclay, M. L., Kirkpatrick, C., & Begg, E. J. (1999). Once daily aminoglycoside therapy: Is it less toxic than multiple daily doses and how should it be monitored? Clinical Pharmacokinetics, 36(2), 89-98.

1998

Journal - Research Article

Tournadre, J.-P., Barclay, M. L., Bouletreau, P., & Chassard, D. (1998). Lower oesophageal sphincter tone increases after induction of anaesthesia in pigs with full stomach. Canadian Journal of Anesthesia / Journal canadien d'anesthésie, 45(5 Part 1), 479-482.

Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Robertshawe, B. J., Kirkpatrick, C. M. J., Pattemore, P. K., & Charles, B. (1998). Population pharmacokinetics of tobramycin in children with cystic fibrosis with relation to once-daily dosing. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 5, (pp. 55). [Abstract]

1997

Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Fraser, R., Tournadre, J.-P., Young, R., Jury, P., Ferguson, L., … Dent, J. (1997). Gastro-intestinal motility and early duodenal feeding after major abdominal surgery. Anesthesiology. 87, (pp. A223). [Abstract]

Tournadre, J.-P., Barclay, M. L., Fraser, R., Young, R. J., Jury, P., Fergusson, L., … Dent, J. (1997). Motricité gastro-intestinale lors de la nutrition entérale précoce apres chirurgie abdominale. Annales Francaises d'Anesthesie et de Reanimation. 16, (pp. 686). [Abstract]

Barclay, M. L., Dent, J., Bochner, F., & Somogyi, A. A. (1997). Investigation of gastric lumen pharmacokinetics using a novel multilumen aspiration/infusion catheter technique. Proceedings of the Australasian SOciety of CLinical and Experimental Pharmacologists and Toxicologists. 4, (pp. 35). [Abstract]

1996

Journal - Research Article

Barclay, M. L., Begg, E. J., Chambers, S. T., & Peddie, B. A. (1996). The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas Aeruginosa in vitro. Journal of Antimicrobial Chemotherapy, 38(5), 853-858.

Bailey, R. R., Begg, E. J., Smith, A. H., Robson, R. A., Lynn, K. L., Chambers, S., Barclay, M. L., & Hornibrook, J. (1996). Prospective, randomised, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Clinical Nephrology, 46, 183-186.

Barclay, M. L., Begg, E. J., Chambers, S., Thornley, P. E., Pattemore, P. K., & Grimwood, K. (1996). Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy, 37, 1155-1164.

1995

Journal - Research Article

Barclay, M. L., Begg, E. J., Duffull, S. B., & Buttimore, R. C. (1995). Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Australian & New Zealand Journal of Medicine, 25, 230-235.